UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________

FORM 10-Q

_____________________________________________________

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~December 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File No. 000-52082

____________________________________________________

CARDIOVASCULAR SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

____________________________________________________


Delaware						41-1698056
(State or other jurisdiction of						(IRS Employer
incorporation or organization)						Identification No.)

1225 Old Highway 8 Northwest

St. Paul, Minnesota 55112-6416

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (651) 259-1600

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, One-tenth of One Cent ($0.001) Par Value Per Share	CSII	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

The number of shares outstanding of the registrant’s Common Stock, $0.001 par value per share, as of ~~May 2, 2022~~February 7, 2023 was: ~~40,785,123~~41,958,938 shares.

Table of Contents

Cardiovascular Systems, Inc.

Table of Contents


			PAGE
PART I. FINANCIAL INFORMATION
ITEM 1. Consolidated Financial Statements (unaudited)			3
Consolidated Balance Sheets			3
Consolidated Statements of Operations			4
Consolidated Statements of Comprehensive Income			5
Consolidated Statements of Changes in Stockholders’ Equity			6
Consolidated Statements of Cash Flows			8
Notes to Consolidated Financial Statements			9
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			1819
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk			2729
ITEM 4. Controls and Procedures			2730
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings			2831
ITEM 1A. Risk Factors			2831
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds			2833
ITEM 3. Defaults Upon Senior Securities			2834
ITEM 4. Mine Safety Disclosures			2834
ITEM 5. Other Information			2834
ITEM 6. Exhibits			2834
Signatures			3036

Table of Contents

PART I. — FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Cardiovascular Systems, Inc.

Consolidated Balance Sheets

(Dollars in thousands, except per share and share amounts)

(Unaudited)


		March 31, 2022		June 30, 2021			December 31, 2022		June 30, 2022
ASSETS	ASSETS					ASSETS
Current assets	Current assets					Current assets
Cash and cash equivalents	Cash and cash equivalents	$	66,953	$	71,070	Cash and cash equivalents	$	59,843	$	66,424
Marketable securities	Marketable securities	105,098		135,968		Marketable securities	72,159		93,409
Accounts receivable, net	Accounts receivable, net	34,666		40,033		Accounts receivable, net	40,232		39,678
Inventories	Inventories	32,854		32,313		Inventories	41,191		34,567
Prepaid expenses and other current assets	Prepaid expenses and other current assets	5,742		5,285		Prepaid expenses and other current assets	8,535		7,768
Total current assets	Total current assets	245,313		284,669		Total current assets	221,960		241,846
Property and equipment, net	Property and equipment, net	29,097		28,894		Property and equipment, net	30,002		29,035
Intangible assets, net	Intangible assets, net	16,080		15,376		Intangible assets, net	15,043		15,734
Strategic investments	Strategic investments	30,733		20,657		Strategic investments	42,034		33,425
Other assets	Other assets	2,768		2,971		Other assets	2,467		2,637
Total assets	Total assets	$	323,991	$	352,567	Total assets	$	311,506	$	322,677
LIABILITIES AND STOCKHOLDERS’ EQUITY	LIABILITIES AND STOCKHOLDERS’ EQUITY					LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities	Current liabilities					Current liabilities
Accounts payable	Accounts payable	$	13,598	$	14,061	Accounts payable	$	17,087	$	14,383
Accrued expenses	Accrued expenses	30,011		38,189		Accrued expenses	19,149		23,464
Deferred revenue	Deferred revenue	2,812		2,400		Deferred revenue	525		2,107
Total current liabilities	Total current liabilities	46,421		54,650		Total current liabilities	36,761		39,954
Long-term liabilities	Long-term liabilities					Long-term liabilities
Financing obligation	Financing obligation	20,385		20,596		Financing obligation	20,117		20,298
Deferred revenue	Deferred revenue	—		2,194		Deferred revenue	3,365		—
Other liabilities	Other liabilities	3,687		4,169		Other liabilities	11,874		12,945
Total liabilities	Total liabilities	70,493		81,609		Total liabilities	72,117		73,197
Commitments and contingencies (see Note 10)		0		0
Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 40,784,179 at March 31, 2022 and 40,215,554 at June 30, 2021, respectively		39		39
Commitments and contingencies (see Note 9)						Commitments and contingencies (see Note 9)
Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 41,965,948 at December 31, 2022 and 40,965,202 at June 30, 2022, respectively						Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 41,965,948 at December 31, 2022 and 40,965,202 at June 30, 2022, respectively	40		40
Additional paid in capital	Additional paid in capital	667,552		652,288		Additional paid in capital	682,932		673,388
Accumulated other comprehensive income	Accumulated other comprehensive income	(212)		11		Accumulated other comprehensive income	(170)		(268)
Accumulated deficit	Accumulated deficit	(413,881)		(381,380)		Accumulated deficit	(443,413)		(423,680)
Total stockholders’ equity	Total stockholders’ equity	253,498		270,958		Total stockholders’ equity	239,389		249,480
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	323,991	$	352,567	Total liabilities and stockholders’ equity	$	311,506	$	322,677

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Cardiovascular Systems, Inc.

Consolidated Statements of Operations

(Dollars in thousands, except per share and share amounts)

(Unaudited)


		Three Months Ended				Nine Months Ended					Three Months Ended				Six Months Ended
		March 31,				March 31,					December 31,				December 31,
		2022		2021		2022		2021			2022		2021		2022		2021
Net revenues	Net revenues	$	56,221	$	63,273	$	173,726	$	187,986	Net revenues	$	61,453	$	59,135	$	121,126	$	117,505
Cost of goods sold	Cost of goods sold	14,790		14,013		47,171		40,497		Cost of goods sold	18,461		18,073		35,159		32,381
Gross profit	Gross profit	41,431		49,260		126,555		147,489		Gross profit	42,992		41,062		85,967		85,124
Expenses:	Expenses:									Expenses:
Selling, general and administrative	Selling, general and administrative	41,680		41,442		123,933		121,785		Selling, general and administrative	41,642		40,402		86,117		82,253
Research and development	Research and development	9,052		13,163		27,947		31,816		Research and development	9,533		8,873		18,589		18,895
Amortization of intangible assets	Amortization of intangible assets	346		304		996		912		Amortization of intangible assets	345		346		691		650
Total expenses	Total expenses	51,078		54,909		152,876		154,513		Total expenses	51,520		49,621		105,397		101,798
Loss from operations	Loss from operations	(9,647)		(5,649)		(26,321)		(7,024)		Loss from operations	(8,528)		(8,559)		(19,430)		(16,674)
Other (income) expense, net:	Other (income) expense, net:									Other (income) expense, net:
Interest expense	Interest expense	408		412		1,227		1,323		Interest expense	404		409		810		819
Interest income and other, net	Interest income and other, net	(460)		(120)		(567)		(400)		Interest income and other, net	(1,093)		(64)		(1,751)		(107)
Total other (income) expense, net	Total other (income) expense, net	(52)		292		660		923		Total other (income) expense, net	(689)		345		(941)		712
Loss before income taxes	Loss before income taxes	(9,595)		(5,941)		(26,981)		(7,947)		Loss before income taxes	(7,839)		(8,904)		(18,489)		(17,386)
Provision for income taxes	Provision for income taxes	63		63		262		189		Provision for income taxes	49		63		30		199
Net loss	Net loss	$	(9,658)	$	(6,004)	$	(27,243)	$	(8,136)	Net loss	$	(7,888)	$	(8,967)	$	(18,519)	$	(17,585)

Basic and diluted earnings per share	Basic and diluted earnings per share	$	(0.25)	$	(0.15)	$	(0.70)	$	(0.21)	Basic and diluted earnings per share	$	(0.20)	$	(0.23)	$	(0.47)	$	(0.45)

Basic and diluted weighted average shares outstanding	Basic and diluted weighted average shares outstanding	39,287,632		38,911,454		39,190,865		38,800,622		Basic and diluted weighted average shares outstanding	39,663,565		39,199,593		39,635,293		39,143,533

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Cardiovascular Systems, Inc.

Consolidated Statements of Comprehensive Income

(Dollars in thousands)

(Unaudited)


		Three Months Ended				Nine Months Ended					Three Months Ended				Six Months Ended
		March 31,				March 31,					December 31,				December 31,
		2022		2021		2022		2021			2022		2021		2022		2021
Net loss	Net loss	$	(9,658)	$	(6,004)	$	(27,243)	$	(8,136)	Net loss	$	(7,888)	$	(8,967)	$	(18,519)	$	(17,585)
Other comprehensive loss:
Unrealized loss on available-for-sale debt securities		(154)		(72)		(223)		(226)
Other comprehensive income (loss):										Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale debt securities										Unrealized gain (loss) on available-for-sale debt securities	103		(52)		106		(69)
Foreign currency translation adjustments										Foreign currency translation adjustments	(2)		—		(8)		—

Comprehensive loss	Comprehensive loss	$	(9,812)	$	(6,076)	$	(27,466)	$	(8,362)	Comprehensive loss	$	(7,787)	$	(9,019)	$	(18,421)	$	(17,654)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Cardiovascular Systems, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(Dollars in thousands, except per share amounts)

(Unaudited)


		Common Stock		Additional Paid In Capital				Accumulated Other Comprehensive Income				Accumulated Deficit		Total			Common Stock		Additional Paid In Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total

Balances at June 30, 2021		$	39			$	652,288			$	11						$	(381,380)	$	270,958
Balances at June 30, 2022																Balances at June 30, 2022	$	40	$	673,388	$	(268)	$	(423,680)	$	249,480
Stock-based compensation related to restricted stock awards, net	Stock-based compensation related to restricted stock awards, net	—		5,523				—				—		5,523		Stock-based compensation related to restricted stock awards, net	—		4,324		—		—		4,324
Shares withheld for payroll taxes	Shares withheld for payroll taxes	—		—				—				(4,990)		(4,990)		Shares withheld for payroll taxes	—		—		—		(1,191)		(1,191)
Employee stock purchase plan activity	Employee stock purchase plan activity	—		324				—				—		324		Employee stock purchase plan activity	—		174		—		—		174
Unrealized loss on available-for-sale debt securities		—		—				(17)				—		(17)
Exercise of stock options		—		12				—				—		12
Unrealized gain on available-for-sale debt securities																Unrealized gain on available-for-sale debt securities	—		—		3		—		3
Foreign currency translation adjustments																Foreign currency translation adjustments	—		—		(6)		—		(6)

Net loss	Net loss	—		—				—				(8,618)		(8,618)		Net loss	—		—		—		(10,631)		(10,631)
Balances at September 30, 2021		$	39	$	658,147			$	(6)			$	(394,988)	$	263,192
Balances at September 30, 2022																Balances at September 30, 2022	$	40	$	677,886	$	(271)	$	(435,502)	$	242,153
Stock-based compensation related to restricted stock awards, net	Stock-based compensation related to restricted stock awards, net	—		3,659				—				—		3,659		Stock-based compensation related to restricted stock awards, net	—		3,547		—		—		3,547
Shares withheld for payroll taxes	Shares withheld for payroll taxes	—		—				—				(161)		(161)		Shares withheld for payroll taxes	—		—		—		(23)		(23)
Employee stock purchase plan activity	Employee stock purchase plan activity	—		1,854				—				—		1,854		Employee stock purchase plan activity	—		1,499		—		—		1,499
Unrealized loss on available-for-sale debt securities		—		—				(52)				—		(52)
Unrealized gain on available-for-sale debt securities																Unrealized gain on available-for-sale debt securities	—		—		103		—		103
Foreign currency translation adjustments																Foreign currency translation adjustments	—		—		(2)		—		(2)
Net loss	Net loss	—		—				—				(8,967)		(8,967)		Net loss	—		—		—		(7,888)		(7,888)
Balances at December 31, 2021		$	39	$	663,660			$	(58)			$	(404,116)	$	259,525
Stock-based compensation related to restricted stock awards, net		—		3,538				—				—		3,538
Shares withheld for payroll taxes		—		—				—				(107)		(107)
Employee stock purchase plan activity		—		354				—				—		354
Unrealized loss on available-for-sale debt securities		—		—				(154)				—		(154)
Net loss		—		—				—				(9,658)		(9,658)
Balances at March 31, 2022		$	39	$	667,552			$	(212)			$	(413,881)	$	253,498
Balances at December 31, 2022																Balances at December 31, 2022	$	40	$	682,932	$	(170)	$	(443,413)	$	239,389

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Cardiovascular Systems, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(Dollars in thousands, except per share amounts)

(Unaudited)


		Common Stock		Additional Paid In Capital				Accumulated Other Comprehensive Income (Loss)				Accumulated Deficit		Total			Common Stock		Additional Paid In Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total

Balances at June 30, 2020		$	39			$	631,559			$	269						$	(363,075)	$	268,792
Balances at June 30, 2021																Balances at June 30, 2021	$	39	$	652,288	$	11	$	(381,380)	$	270,958
Stock-based compensation related to restricted stock awards, net	Stock-based compensation related to restricted stock awards, net	—		4,836				—				—		4,836		Stock-based compensation related to restricted stock awards, net	—		5,523		—		—		5,523
Shares withheld for payroll taxes	Shares withheld for payroll taxes	—		—				—				(3,410)		(3,410)		Shares withheld for payroll taxes	—		—		—		(4,990)		(4,990)
Employee stock purchase plan activity	Employee stock purchase plan activity	—		332				—				—		332		Employee stock purchase plan activity	—		324		—		—		324
Unrealized loss on available-for-sale debt securities	Unrealized loss on available-for-sale debt securities	—		—				(69)				—		(69)		Unrealized loss on available-for-sale debt securities	—		—		(17)		—		(17)
Exercise of stock options																Exercise of stock options	—		12		—		—		12

Net loss	Net loss	—		—				—				(2,076)		(2,076)		Net loss	—		—		—		(8,618)		(8,618)
Balances at September 30, 2020		$	39	$	636,727			$	200			$	(368,561)	$	268,405
Balances at September 30, 2021																Balances at September 30, 2021	$	39	$	658,147	$	(6)	$	(394,988)	$	263,192
Stock-based compensation related to restricted stock awards, net	Stock-based compensation related to restricted stock awards, net	—		3,545				—				—		3,545		Stock-based compensation related to restricted stock awards, net	—		3,659		—		—		3,659
Shares withheld for payroll taxes	Shares withheld for payroll taxes	—		—				—				(407)		(407)		Shares withheld for payroll taxes	—		—		—		(161)		(161)
Employee stock purchase plan activity	Employee stock purchase plan activity	—		2,430				—				—		2,430		Employee stock purchase plan activity	—		1,854		—		—		1,854
Unrealized loss on available-for-sale debt securities	Unrealized loss on available-for-sale debt securities	—		—				(85)				—		(85)		Unrealized loss on available-for-sale debt securities	—		—		(52)		—		(52)
Net loss	Net loss	—		—				—				(56)		(56)		Net loss	—		—		—		(8,967)		(8,967)
Balances at December 31, 2020		$	39	$	642,702			$	115			$	(369,024)	$	273,832
Stock-based compensation related to restricted stock awards, net		—		3,332				—				—		3,332
Shares withheld for payroll taxes		—		—				—				(1,009)		(1,009)
Employee stock purchase plan activity		—		372				—				—		372
Unrealized loss on available-for-sale debt securities		—		—				(72)				—		(72)
Net loss		—		—				—				(6,004)		(6,004)
Balances at March 31, 2021		$	39	$	646,406			$	43			$	(376,037)	$	270,451
Balances at December 31, 2021																Balances at December 31, 2021	$	39	$	663,660	$	(58)	$	(404,116)	$	259,525

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Cardiovascular Systems, Inc.

Consolidated Statements of Cash Flows

(Dollars in thousands)

(Unaudited)


		Nine Months Ended					Six Months Ended
		March 31,					December 31,
		2022		2021			2022		2021
Cash flows from operating activities	Cash flows from operating activities					Cash flows from operating activities
Net loss	Net loss	$	(27,243)	$	(8,136)	Net loss	$	(18,519)	$	(17,585)
Adjustments to reconcile net loss to net cash from operating activities	Adjustments to reconcile net loss to net cash from operating activities					Adjustments to reconcile net loss to net cash from operating activities
Depreciation of property and equipment	Depreciation of property and equipment	2,835		2,231		Depreciation of property and equipment	1,797		1,895
Amortization of intangible assets	Amortization of intangible assets	996		912		Amortization of intangible assets	691		650
Stock-based compensation	Stock-based compensation	13,804		12,488		Stock-based compensation	7,985		9,912
Charges incurred in connection with acquired IPR&D		—		3,353

Provision for doubtful accounts	Provision for doubtful accounts	50		—		Provision for doubtful accounts	50		—
(Gain) loss on disposal of equipment		(15)		138

Amortization of premium (accretion of discount) on marketable securities	Amortization of premium (accretion of discount) on marketable securities	1,106		1,026		Amortization of premium (accretion of discount) on marketable securities	(615)		800
Other	Other	(402)		—		Other	(69)		(26)

Changes in assets and liabilities	Changes in assets and liabilities					Changes in assets and liabilities
Accounts receivable	Accounts receivable	5,317		(12,844)		Accounts receivable	(612)		5,089
Inventories	Inventories	(541)		(5,661)		Inventories	(6,624)		642
Prepaid expenses and other assets	Prepaid expenses and other assets	467		425		Prepaid expenses and other assets	(278)		950
Accounts payable	Accounts payable	(266)		1,147		Accounts payable	2,667		(1,525)
Accrued expenses and other liabilities	Accrued expenses and other liabilities	(8,769)		3,910		Accrued expenses and other liabilities	(5,456)		(11,996)
Deferred revenue	Deferred revenue	(1,782)		(1,409)		Deferred revenue	1,783		(1,121)
Net cash used in operating activities	Net cash used in operating activities	(14,443)		(2,420)		Net cash used in operating activities	(17,200)		(12,315)
Cash flows from investing activities	Cash flows from investing activities					Cash flows from investing activities
Purchases of property and equipment	Purchases of property and equipment	(3,220)		(2,758)		Purchases of property and equipment	(2,727)		(2,426)
Acquisitions	Acquisitions	(1,700)		(3,353)		Acquisitions	—		(1,700)
Investments in strategic ventures	Investments in strategic ventures	(9,674)		(8,374)		Investments in strategic ventures	(8,540)		(8,999)
Purchases of marketable securities	Purchases of marketable securities	(85,076)		(156,628)		Purchases of marketable securities	(52,523)		(50,844)
Sales of marketable securities	Sales of marketable securities	13,692		4,885		Sales of marketable securities	14,389		6,817
Maturities of marketable securities	Maturities of marketable securities	100,462		61,350		Maturities of marketable securities	59,875		68,261

Net cash provided by (used in) investing activities		14,484		(104,878)
Net cash provided by investing activities						Net cash provided by investing activities	10,474		11,109
Cash flows from financing activities	Cash flows from financing activities					Cash flows from financing activities
Proceeds from employee stock purchase plan	Proceeds from employee stock purchase plan	1,242		2,098		Proceeds from employee stock purchase plan	1,499		1,242
Payments of employee taxes related to vested restricted stock	Payments of employee taxes related to vested restricted stock	(5,258)		(4,826)		Payments of employee taxes related to vested restricted stock	(1,214)		(5,151)
Exercise of stock options	Exercise of stock options	12		—		Exercise of stock options	—		12

Principal payments made on financing obligation	Principal payments made on financing obligation	(154)		(104)		Principal payments made on financing obligation	(140)		(102)
Net cash used in financing activities		(4,158)		(2,832)
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	145		(3,999)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	(4,117)		(110,130)		Net change in cash and cash equivalents	(6,581)		(5,205)
Cash and cash equivalents	Cash and cash equivalents					Cash and cash equivalents
Beginning of period	Beginning of period	71,070		185,463		Beginning of period	66,424		71,070
End of period	End of period	$	66,953	$	75,333	End of period	$	59,843	$	65,865

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

CARDIOVASCULAR SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(For the ~~Nine~~Six Months Ended ~~March~~December 31, 2022 and 2021)

(Dollars in thousands, except per share and share amounts)

(Unaudited)

1. Basis of Presentation

Cardiovascular Systems, Inc. (the “Company”), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Atherectomy Systems (“OAS”) treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The Company prepared the unaudited interim consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The year-end consolidated balance sheet was derived from the Company’s audited consolidated financial statements, but does not include all disclosures as required by GAAP. These interim consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary for a fair statement of the Company’s consolidated financial position, the results of its operations, its changes in stockholders’ equity, and its cash flows for the interim periods. ~~Certain amounts in the prior years' consolidated financial statements have been reclassified to conform to the current year presentation.~~ These interim consolidated financial statements should be read in conjunction with the consolidated annual financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended June 30, ~~2021.~~2022. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company has been impacted by the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on the Company's customers and markets. The Company has made estimates of the impact of COVID-19 within these consolidated financial statements and there may be changes to those estimates in future periods. Actual results could differ from those estimates.

2. Selected Consolidated Financial Statement Information

Accounts Receivable, Net

Accounts receivable consists of the following:


		March 31,		June 30,			December 31,		June 30,
		2022		2021			2022		2022
Accounts receivable	Accounts receivable	$	35,871	$	41,634	Accounts receivable	$	41,504	$	40,974
Less: Allowance for doubtful accounts	Less: Allowance for doubtful accounts	(1,205)		(1,601)		Less: Allowance for doubtful accounts	(1,272)		(1,296)
Accounts receivable, net	Accounts receivable, net	$	34,666	$	40,033	Accounts receivable, net	$	40,232	$	39,678

Table of Contents

Inventories

Inventories consist of the following:


		March 31,		June 30,			December 31,		June 30,
		2022		2021			2022		2022
Raw materials	Raw materials	$	12,337	$	11,621	Raw materials	$	16,340	$	13,780
Work in process	Work in process	3,781		3,469		Work in process	2,404		2,785
Finished goods	Finished goods	16,736		17,223		Finished goods	22,447		18,002
Inventories	Inventories	$	32,854	$	32,313	Inventories	$	41,191	$	34,567

~~WIRION Recall~~

~~In November 2021, the Company initiated a voluntary recall of unused WIRION embolic protection systems. In connection with the recall, the Company recorded a~~The total inventory reserve ~~for approximately $2,849 during the nine months ended March~~at December 31, 2022 ~~which amount represents inventory that has no future intended use.~~and June 30, 2022 was $3,313 and $4,128, respectively.

Property and Equipment, Net

Property and equipment consists of the following:


		March 31,		June 30,			December 31,		June 30,
		2022		2021			2022		2022
Land	Land	$	572	$	572	Land	$	572	$	572
Building	Building	22,420		22,420		Building	22,420		22,420
Equipment	Equipment	24,045		21,203		Equipment	25,400		24,340
Furniture	Furniture	3,376		3,376		Furniture	3,376		3,376
Leasehold improvements	Leasehold improvements	812		804		Leasehold improvements	812		812
Construction in progress	Construction in progress	2,175		2,848		Construction in progress	4,376		2,670
		53,400		51,223			56,956		54,190
Less: Accumulated depreciation	Less: Accumulated depreciation	(24,303)		(22,329)		Less: Accumulated depreciation	(26,954)		(25,155)
Property and equipment, net	Property and equipment, net	$	29,097	$	28,894	Property and equipment, net	$	30,002	$	29,035

Accrued Expenses

Accrued expenses consist of the following:


		March 31,		June 30,			December 31,		June 30,
		2022		2021			2022		2022
Acquisition consideration		$	10,000	$	10,000

Commissions	Commissions	4,784		7,869		Commissions	6,513		8,104
Salaries and bonus	Salaries and bonus	6,726		11,699		Salaries and bonus	5,675		8,082
Accrued vacation	Accrued vacation	2,349		3,011		Accrued vacation	2,336		2,345
Clinical Studies		1,255		1,478
Accrued excise, sales and other taxes	Accrued excise, sales and other taxes	960		1,464		Accrued excise, sales and other taxes	847		953
Clinical studies						Clinical studies	1,009		1,082

Other accrued expenses		3,937		2,668
Other						Other	2,769		2,898
Accrued expenses	Accrued expenses	$	30,011	$	38,189	Accrued expenses	$	19,149	$	23,464

Other Liabilities

~~Table of Contents~~

WIRION Acquisition Consideration

Following the successful completion of the manufacturing transfer of the WIRION system to the Company, the Company has agreed to pay an additional consideration of $10,000, half of which may be paid by the Company through an issuance of shares of its common stock. The Company reviewed this liability in response to the voluntary recall of the WIRION system ~~referred to above~~ and determined that it remains probable and appropriately recorded in ~~accrued~~other liabilities as of ~~March~~December 31, 2022, although this payment will be made at a later date than originally anticipated due to the recall.

Table of Contents

3. Revenue

The following table disaggregates the Company’s net revenues by product category and geography for the following periods:


		Three Months Ended				Nine Months Ended					Three Months Ended				Six Months Ended
		March 31,				March 31,					December 31,				December 31,
Product Category	Product Category	2022		2021		2022		2021		Product Category	2022		2021		2022		2021
Peripheral	Peripheral	$	37,370	$	42,295	$	115,282	$	129,183	Peripheral	$	38,452	$	38,903	$	77,236	$	77,912
Coronary	Coronary	18,851		20,978		58,444		58,803		Coronary	23,001		20,232		43,890		39,593
Total net revenues	Total net revenues	$	56,221	$	63,273	$	173,726	$	187,986	Total net revenues	$	61,453	$	59,135	$	121,126	$	117,505

Geography	Geography									Geography
United States	United States	$	51,843	$	59,593	$	162,356	$	180,331	United States	$	56,329	$	55,471	$	111,356	$	110,513
International	International	4,378		3,680		11,370		7,655		International	5,124		3,664		9,770		6,992
Total net revenues	Total net revenues	$	56,221	$	63,273	$	173,726	$	187,986	Total net revenues	$	61,453	$	59,135	$	121,126	$	117,505

Revenue of ~~$1,782~~$2,107 was recognized in the ~~nine~~six months ended ~~March~~December 31, 2022 that was deferred as of June 30, ~~2021.~~2022. On December 13, 2022, we signed a distribution agreement with Otsuka Medical Devices Co., Ltd. ("Otsuka"). Effective February 1, 2023 upon expiration of Medikit's distribution agreement, Otsuka became our exclusive Japan distributor. The Company received a $4,000 upfront payment which the Company has recorded as deferred revenue and classified as current and long-term based on its expectation of when revenue will be recognized. Revenue of $110 was recognized in the three months ended December 31, 2022 related to this upfront payment. As of ~~March~~December 31, 2022 and June 30, ~~2021,~~2022, the Company had a liability of ~~$1,254~~$991 and ~~$1,985,~~$1,315, respectively, related to estimates of variable consideration which are recorded within accounts payable on the consolidated balance sheet.

4. ~~Acquisitions~~

~~Peripheral Support Catheters~~

~~During fiscal 2021, the Company acquired a line of peripheral support catheters from WavePoint Medical, LLC (“WavePoint”) and also engaged WavePoint to develop a portfolio of specialty catheters.~~

The acquisition of peripheral support catheters was accounted for as an asset acquisition. As consideration in this transaction, the Company made an upfront payment of $3,353 to WavePoint, which was accounted for as a charge incurred in connection with acquired in process research and development ("IPR&D"). During the nine months ended March 31, 2022, the peripheral support catheters received 510(k) clearance and the Company made an additional $1,700 payment to WavePoint pursuant to the terms of the parties' agreement, which amount was capitalized as developed technology.

5. Intangible Assets

The Company’s finite-lived intangible assets are stated at cost less accumulated amortization and include developed technology and trade name assets acquired in asset acquisitions, as well as costs incurred to obtain patents. Developed technology and trade name assets are amortized over 10 years to 15 years. Patent costs are amortized beginning at the time of patent approval over a useful life not exceeding 20 years.

~~Table of Contents~~

The components of intangible assets, net are as follows:


		March 31, 2022						June 30, 2021							December 31, 2022						June 30, 2022
		Gross Carrying Amount		Accumulated Amortization		Net Book Value		Gross Carrying Amount		Accumulated Amortization		Net Book Value			Gross Carrying Amount		Accumulated Amortization		Net Book Value		Gross Carrying Amount		Accumulated Amortization		Net Book Value
Developed technology	Developed technology	$	17,324	$	(2,863)	$	14,461	$	15,624	$	(1,997)	$	13,627	Developed technology	$	17,324	$	(3,771)	$	13,553	$	17,324	$	(3,165)	$	14,159
Patents	Patents	1,866		(872)		994		1,866		(780)		1,086		Patents	1,866		(963)		903		1,866		(903)		963
Trade name	Trade name	760		(135)		625		760		(97)		663		Trade name	760		(173)		587		760		(148)		612
Total intangible assets, net	Total intangible assets, net	$	19,950	$	(3,870)	$	16,080	$	18,250	$	(2,874)	$	15,376	Total intangible assets, net	$	19,950	$	(4,907)	$	15,043	$	19,950	$	(4,216)	$	15,734

Amortization expense expected for the next five years and thereafter is as follows:


Remainder of fiscal ~~2022~~2023	$	~~345~~
~~Fiscal 2023~~	~~1,381~~690
Fiscal 2024	1,377
Fiscal 2025	1,374
Fiscal 2026	1,373
Fiscal 2027	1,371
Thereafter	~~10,230~~8,858
	$	~~16,080~~15,043

Table of Contents

5. Debt

Revolving Credit Facility

In March 2017, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). In March 2020, the Company entered into the First Amendment to the Loan Agreement (the "Amendment"). The Amendment extended the maturity date of the Loan Agreement by two years, to March 31, 2022, and increased the maximum amount available under the senior, secured revolving credit facility (the “Revolver”) to $50,000 (the “Maximum Dollar Amount”). In March 2022, the Company entered into the Second Amendment to the Loan Agreement (the "Second Amendment"). The Second Amendment extended the maturity date of the Loan Agreement by one year, to March 31, 2023.

Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.75%. Interest on borrowings is due monthly and the principal balance is due at maturity. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. The Company will incur a fee equal to 1.5% of the Maximum Dollar Amount upon termination of the Loan Agreement, as amended by the Second Amendment (the "Amended Loan Agreement"), or the Revolver for any reason prior to the date that is fifteen days prior to the maturity date, unless refinanced with SVB.

The Company’s obligations under the Amended Loan Agreement are secured by certain of the Company’s assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include the Company’s intellectual property, but the Company has agreed not to encumber its intellectual property without the consent of SVB. The Amended Loan Agreement contains customary covenants limiting the Company’s ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of its business. In addition, the Amended Loan Agreement contains financial covenants requiring the Company to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10,000 or (ii) minimum trailing three-month Adjusted EBITDA of $1,000. If the Company does not comply with the various covenants under the Amended Loan Agreement or an event of default under the Amended Loan Agreement occurs, such as a material adverse change, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights and the other terms and conditions of the Amended Loan Agreement, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral.

~~Table of Contents~~

The Company is required to pay a fee equal to 0.15% per annum on the unused portion of the Revolver, payable quarterly in arrears. The Company is not obligated to draw any funds under the Revolver and has not done so under the Revolver since entering into the Loan Agreement. No amounts are outstanding as of ~~March~~December 31, 2022.

Financing Obligation

In ~~March 2017, in~~ connection with the sale of the Company’s headquarters facility in St. Paul, Minnesota (the “Facility”), the Company entered into a Lease Agreement to lease the Facility. The Lease Agreement has an initial term of 15 years, with 4four consecutive renewal options of 5 years each at the Company’s option, with a base annual rent in the first year of $1,638 and annual escalations of 3% thereafter. Rent during subsequent renewal terms will be at the then fair market rental rate. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Facility as a financing transaction where the assets remain on the Company’s balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. The effective interest rate is 7.89%. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet.

Table of Contents

Payments under the initial term of the Lease Agreement as of ~~March~~December 31, 2022 are as follows:


Remainder of fiscal ~~2022~~2023	$	~~475~~
~~Fiscal 2023~~	~~1,913~~963
Fiscal 2024	1,970
Fiscal 2025	2,029
Fiscal 2026	2,090
Fiscal 2027	2,153
Thereafter	~~13,286~~11,133
	$	~~21,763~~20,338

7.6. Marketable Securities & Fair Value Measurements

The Company’s marketable securities are classified on the consolidated balance sheet as follows:


		March 31,		June 30,			December 31,		June 30,
		2022		2021			2022		2022
Short-term available-for-sale debt securities	Short-term available-for-sale debt securities	$	94,236	$	129,908	Short-term available-for-sale debt securities	$	69,688	$	88,375
Long-term available-for-sale debt securities	Long-term available-for-sale debt securities	10,621		5,748		Long-term available-for-sale debt securities	2,331		4,810
Available-for-sale debt securities	Available-for-sale debt securities	104,857		135,656		Available-for-sale debt securities	72,019		93,185
Mutual funds	Mutual funds	241		312		Mutual funds	140		224
Total marketable securities	Total marketable securities	$	105,098	$	135,968	Total marketable securities	$	72,159	$	93,409

Available-for-sale debt securities are invested in the following financial instruments:


				As of March 31, 2022									As of December 31, 2022
		Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value			Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	Commercial paper	$	37,450	$	—	$	—	$	37,450	Commercial paper	$	34,221	$	—	$	—	$	34,221
U.S. government securities										U.S. government securities	17,004		1		(40)		16,965
Corporate debt	Corporate debt	44,982		1		(117)		44,866		Corporate debt	18,601		—		(99)		18,502
Asset backed securities	Asset backed securities	16,665		—		(79)		16,586		Asset backed securities	2,354		—		(23)		2,331
U.S. government securities		5,972		—		(17)		5,955
Total available-for-sale debt securities	Total available-for-sale debt securities	$	105,069	$	1	$	(213)	$	104,857	Total available-for-sale debt securities	$	72,180	$	1	$	(162)	$	72,019


			As of June 30, 2022
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	36,800	$	—	$	—	$	36,800
U.S. government securities	14,994		—		(67)		14,927
Corporate debt	27,193		—		(142)		27,051
Asset backed securities	14,465		—		(58)		14,407
Total available-for-sale debt securities	$	93,452	$	—	$	(267)	$	93,185

Table of Contents

As of June 30, 2021
Amortized Cost Unrealized Gains Unrealized Losses Fair Value
Commercial paper $ 47,361 $ — $ — $ 47,361
U.S. government securities 20,229 1 — 20,230
Corporate debt 57,134 12 (12) 57,134
Asset backed securities 10,922 10 (1) 10,931
Total available-for-sale debt securities $ 135,646 $ 23 $ (13) $ 135,656

The following table provides information by level for the Company’s marketable securities that were measured at fair value on a recurring basis:


				Fair Value Measurements as of March 31, 2022 Using Inputs Considered as									Fair Value Measurements as of December 31, 2022 Using Inputs Considered as
		Fair Value		Level 1		Level 2		Level 3			Fair Value		Level 1		Level 2		Level 3
Commercial paper	Commercial paper	$	37,450	$	—	$	37,450	$	—	Commercial paper	$	34,221	$	—	$	34,221	$	—
U.S. government securities	U.S. government securities	5,955		—		5,955		—		U.S. government securities	16,965		—		16,965		—
Corporate debt	Corporate debt	44,866		—		44,866		—		Corporate debt	18,502		—		18,502		—
Asset backed securities	Asset backed securities	16,586		—		16,586		—		Asset backed securities	2,331		—		2,331		—
Mutual funds	Mutual funds	241		124		117		—		Mutual funds	140		81		59		—
Total marketable securities	Total marketable securities	$	105,098	$	124	$	104,974	$	—	Total marketable securities	$	72,159	$	81	$	72,078	$	—


				Fair Value Measurements as of June 30, 2021 Using Inputs Considered as									Fair Value Measurements as of June 30, 2022 Using Inputs Considered as
		Fair Value		Level 1		Level 2		Level 3			Fair Value		Level 1		Level 2		Level 3
Commercial paper	Commercial paper	$	47,361	$	—	$	47,361	$	—	Commercial paper	$	36,800	$	—	$	36,800	$	—
U.S. government securities	U.S. government securities	20,230		—		20,230		—		U.S. government securities	14,927		—		14,927		—
Corporate debt	Corporate debt	57,134		—		57,134		—		Corporate debt	27,051		—		27,051		—
Asset backed securities	Asset backed securities	10,931		—		10,931		—		Asset backed securities	14,407		—		14,407		—
Mutual funds	Mutual funds	312		136		176		—		Mutual funds	224		108		116		—
Total marketable securities	Total marketable securities	$	135,968	$	136	$	135,832	$	—	Total marketable securities	$	93,409	$	108	$	93,301	$	—

The Company’s marketable securities classified within Level 1 are valued using real-time quotes for transactions in active exchange markets. Marketable securities within Level 2 are valued using readily available pricing sources. There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the ~~nine~~six months ended ~~March~~December 31, 2022. Any transfers between levels would be recognized on the date of the event or when a change in circumstances causes a transfer.

Strategic Investments

The Company holds equity investments that do not have readily determined fair values. The Company has elected to measure these investments at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is reviewed each reporting period by performing a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired.

As of ~~March~~December 31, 2022 and June 30, ~~2021,~~2022, the carrying value of these investments was ~~$12,353~~$12,503 and ~~$11,706,~~$12,333, respectively. During the ~~nine~~six months ended ~~March~~December 31, 2022, no impairment indicators were noted. The Company is committed to funding an additional ~~$1,410~~$1,200 into these investments in the future. The Company holds options to acquire all outstanding equity or certain developed technologies with respect to some of these strategic investments.

The Company also holds strategic investments accounted for as available-for-sale debt securities, which had carrying values and approximated fair values of ~~$18,380~~$29,531 and ~~$8,951~~$21,092 as of ~~March~~December 31, 2022 and June 30, ~~2021,~~2022, respectively. On December 30, 2022, the Company entered into a Loan Agreement (the “CVT Loan Agreement”) with Chansu Vascular Technologies, LLC (“CVT”) pursuant to which the Company agreed to loan to CVT up to the principal amount of $49,653, of which the principal amount of $19,653 was outstanding as of the date of such agreement. In January 2023, the Company advanced an additional $15,000 to CVT pursuant to the terms of the CVT Loan Agreement and is obligated to make additional advances of $5,000 on or after July 1, 2023 and $10,000 after CVT’s achievement of a development milestone related to its medical device candidate. The principal amounts outstanding pursuant to the CVT Loan Agreement accrue interest at the rate of 4.35% per annum and all principal and accrued and unpaid interest are due and payable on June 30, 2024. CVT’s obligations under the CVT Loan Agreement are secured by its assets. The fair values of these investments are measured using Level 3 inputs and are not included in the tables above. Impairment is assessed similar to

~~Table of Contents~~

the Company's other strategic investments and no impairment indicators were noted during the ~~nine~~six months ended ~~March~~December 31, 2022.

8.7. Stock-Based Compensation

Table of Contents

On November 15, 2017, the Company’s stockholders approved the 2017 Equity Incentive Plan (the ~~“2017~~“Original 2017 Plan”) for the purpose of granting equity awards to employees, directors and consultants. On March 12, 2020, the Company’s Board of Directors approved the Amended and Restated 2017 Equity Incentive Plan, which ~~amends~~amended and restated the Original 2017 ~~Plan.~~Plan (the "Amended 2017 Plan"). On August 19, 2021, the Company's Board of Directors adopted ana further amendment to the Amended 2017 Plan (as amended, the "2017 Plan"), which was approved by the Company's stockholders on November 11, 2021, that increased the number of shares available for issuance under the 2017 Plan by 1,700,000 shares. As amended to date, the 2017 Plan allows for the granting of up to 3,607,523 shares of common stock as approved by the Board of Directors or committees thereof in the form of nonqualified or incentive stock options, restricted stock awards, restricted stock unit awards, performance share awards, performance unit awards or stock appreciation rights to officers, directors, consultants and employees of the Company. As of December 31, 2022, there were 1,120,174 shares available for grant under the 2017 Plan.

Equity awards classified as restricted stock and performance-based restricted stock are treated as issued shares when granted; however, these shares are not included in the computation of basic weighted average shares outstanding. When shares vest, unless the holder elects to pay the payroll tax liability in cash or through a sale of shares, the Company withholds the appropriate amount of shares to settle the payroll tax liability, on behalf of the individual receiving the shares, as an adjustment to accumulated deficit.

Restricted Stock

The value of each restricted stock award is equal to the fair market value of the Company’s common stock at the date of grant. Vesting of time-based restricted stock awards ranges from one year to three years. The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock’s vesting period.

Restricted stock award activity for the ~~nine~~six months ended ~~March~~December 31, 2022 is as follows:
Number of
Shares Weighted
Average Fair
Value
Outstanding at June 30, 2021 467,942 $ 35.61
Granted 556,934 $ 28.16
Forfeited (97,041) $ 33.89
Vested (227,219) $ 36.44
Outstanding at March 31, 2022 700,616 $ 29.68

~~Performance-Based Restricted Stock~~


	Number of Shares	Weighted Average Fair Value
Outstanding at June 30, 2022	678,899	$	28.88
Granted	669,890	$	16.48
Forfeited	(90,695)	$	23.14
Vested	(194,830)	$	36.23
Outstanding at December 31, 2022	1,063,264	$	20.21

The Company also grants performance-based restricted stock awards to certain executives and other ~~management.~~ management, as summarized below.

Performance-Based Restricted Stock - Total Shareholder Return

In August ~~2021,~~2022, the Company granted an aggregate maximum of ~~306,550~~303,272 shares that vest based on the Company’s total shareholder return relative to total shareholder return of the Company’s peer group (a market condition), as measured by the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, ~~2021~~2022 compared to the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, ~~2024.~~2025. Vesting of these awards will be determined on the date that the Company’s Annual Report on Form 10-K for the fiscal year ending June 30, ~~2024~~2025 is filed.

To calculate the estimated fair value of these restricted stock awards with market conditions, the Company uses a Monte Carlo simulation, which uses the expected average stock prices to estimate the expected number of shares that will vest. The Monte Carlo simulation resulted in an aggregate fair value of approximately ~~$6,090,~~$2,800, which the Company will recognize as expense using the straight-line method over the period that the awards are expected to vest. Stock-based compensation expense related to an award with a market condition will be recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided.

Performance-based restricted stock awards granted in fiscal ~~2021~~2022 and ~~2020~~2021 that are outstanding vest based on the Company’s total shareholder return relative to total shareholder return of the Company’s peer group (a market condition), as measured by the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, ~~2020~~2021 and July 1, ~~2019,~~2020, respectively, compared to the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, ~~2023~~2024 and July 1, ~~2022,~~2023, respectively.

Table of Contents

Performance-Based Restricted Stock - Revenue

In August 2022, the Company granted an aggregate maximum of 303,244 shares that vest based on the Company’s average annual revenue growth during the performance period. Annual revenue growth is measured as the percentage increase in the revenue reported in the Form 10-K for each of the fiscal years ending June 30, 2023, 2024 and 2025, compared to the revenue reported in the Form 10-K for each preceding fiscal year. Vesting of these awards will be determined on the date that the Company’s Annual Report on Form 10-K for the fiscal year ending June 30, 2025 is filed. The Company recognizes expense for awards with performance conditions when it concludes that it is probable that the performance condition will be achieved. Probability is assessed at each reporting period and expense is adjusted for such changes accordingly with a cumulative catch up adjustment.

Performance-based restricted stock award activity for the ~~nine~~six months ended ~~March~~December 31, 2022 is as follows:


		Number of Shares	Weighted Average Fair Value			Number of Shares	Weighted Average Fair Value
Outstanding at June 30, 2021		760,584	$	20.26
Outstanding at June 30, 2022					Outstanding at June 30, 2022	744,215	$	19.89
Granted	Granted	306,550	$	19.87	Granted	606,516	$	12.73
Forfeited	Forfeited	(130,739)	$	22.73	Forfeited	(242,733)	$	27.79
Vested	Vested	(147,001)	$	22.32	Vested	—	$	—
Outstanding at March 31, 2022		789,394	$	19.52
Outstanding at December 31, 2022					Outstanding at December 31, 2022	1,107,998	$	14.24

Unrecognized stock compensation related to unvested stock awards outstanding as of ~~March~~December 31, 2022 was ~~$20,014.~~$20,982.

9.8. Leases

The Company leases its Texas manufacturing facility under an operating lease agreement which expires in April 2026. The Company also leases office equipment under lease agreements that expire at various dates through December 2026. As discussed in Note 6,5, the Company also leases its Minnesota headquarters facility which is accounted for as a financing obligation.

Operating lease right-of-use assets and liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement dates. The Company considers fixed or variable payment terms, prepayments, incentives, and options to extend, terminate or purchase. Renewal, termination or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The Company uses its incremental borrowing rate based on information available at the lease commencement date in determining the present value of lease payments unless the lease provides an implicit interest rate.

Operating lease cost is classified within the consolidated statement of operations based on the nature of the leased asset. The Company's operating lease cost was ~~$387~~$269 and ~~$377~~$258 for the ~~nine~~six months ended ~~March~~December 31, 2022 and 2021, respectively. Cash paid for operating lease liabilities approximated operating lease cost for the ~~nine~~six months ended ~~March~~December 31, 2022. There were ~~$103~~$29 and ~~$2,238~~$54 of operating lease right-of-use assets obtained in exchange for new lease liabilities during the ~~nine~~six months ended ~~March~~December 31, 2022 and 2021, respectively.


		March 31,		June 30,			December 31,		June 30,
		2022		2021			2022		2022
Right-of-use assets	Right-of-use assets					Right-of-use assets
Other assets	Other assets	$	1,936	$	2,212	Other assets	$	1,636	$	1,852
Operating lease liabilities	Operating lease liabilities					Operating lease liabilities
Accrued expenses	Accrued expenses	510		487		Accrued expenses	522		526
Other liabilities	Other liabilities	1,426		1,725		Other liabilities	1,114		1,326
Total operating lease liabilities	Total operating lease liabilities	$	1,936	$	2,212	Total operating lease liabilities	$	1,636	$	1,852

Table of Contents

Future minimum lease payments under the agreements as of ~~March~~December 31, 2022 are as follows:


Remainder of fiscal ~~2022~~2023	$	~~134~~
~~Fiscal 2023~~	~~528~~270
Fiscal 2024	~~503~~514
Fiscal 2025	~~494~~503
Fiscal 2026	~~406~~416
~~Thereafter~~Fiscal 2027	24

Total lease payments	~~2,067~~1,707
Less imputed interest	~~(131)~~(71)
Total operating lease liabilities	$	~~1,936~~1,636

~~Table of Contents~~

As of ~~March~~December 31, 2022, the weighted average remaining lease term for operating leases was ~~4.0~~3.3 years and the weighted average discount rate used to determine operating lease liabilities was ~~2.51%~~2.55%.

~~10.~~9. Commitment and Contingencies

In the ordinary conduct of business, the Company is subject to various lawsuits and claims covering a wide range of matters including, but not limited to, employment claims, commercial disputes and product liability claims. While the outcome of these matters is uncertain, the Company does not believe there are any significant matters as of ~~March~~December 31, 2022 that are probable or estimable, for which the outcome could have a material adverse impact on its consolidated balance sheets or statements of operations.

~~11.~~10. Earnings Per Share

The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations (in thousands except share and per share amounts):


		Three Months Ended				Nine Months Ended					Three Months Ended				Six Months Ended
		March 31,				March 31,					December 31,				December 31,
		2022		2021		2022		2021			2022		2021		2022		2021
Numerator	Numerator									Numerator
Net loss	Net loss	$	(9,658)	$	(6,004)	$	(27,243)	$	(8,136)	Net loss	$	(7,888)	$	(8,967)	$	(18,519)	$	(17,585)
Income allocated to participating securities	Income allocated to participating securities	—		—		—		—		Income allocated to participating securities	—		—		—		—
Net loss available to common stockholders	Net loss available to common stockholders	$	(9,658)	$	(6,004)	$	(27,243)	$	(8,136)	Net loss available to common stockholders	$	(7,888)	$	(8,967)	$	(18,519)	$	(17,585)
Denominator	Denominator									Denominator
Weighted average common shares outstanding – basic	Weighted average common shares outstanding – basic	39,287,632		38,911,454		39,190,865		38,800,622		Weighted average common shares outstanding – basic	39,663,565		39,199,593		39,635,293		39,143,533
Effect of dilutive stock options(1)	Effect of dilutive stock options(1)	—		—		—		—		Effect of dilutive stock options(1)	—		—		—		—
Effect of dilutive restricted stock units(2)	Effect of dilutive restricted stock units(2)	—		—		—		—		Effect of dilutive restricted stock units(2)	—		—		—		—
Effect of performance-based restricted stock awards(3)	Effect of performance-based restricted stock awards(3)	—		—		—		—		Effect of performance-based restricted stock awards(3)	—		—		—		—

Weighted average common shares outstanding – diluted	Weighted average common shares outstanding – diluted	39,287,632		38,911,454		39,190,865		38,800,622		Weighted average common shares outstanding – diluted	39,663,565		39,199,593		39,635,293		39,143,533

Earnings per common share – basic and diluted	Earnings per common share – basic and diluted	$	(0.25)	$	(0.15)	$	(0.70)	$	(0.21)	Earnings per common share – basic and diluted	$	(0.20)	$	(0.23)	$	(0.47)	$	(0.45)

(1)At ~~March~~December 31, 2022 and 2021, ~~76,019~~67,938 and ~~42,528~~79,188 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share for all periods presented because those shares are anti-dilutive.

(2)At ~~March~~December 31, 2022 and 2021, ~~310,415~~279,657 and ~~282,763~~310,415 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share for all periods presented because those shares are anti-dilutive.

(3)At ~~March~~December 31, 2022 and 2021, ~~789,394~~1,107,998 and ~~760,584~~820,586 performance-based restricted stock awards, respectively, were outstanding. The effect of the potential vesting of these awards has been excluded from the calculation of diluted loss per share for all periods presented because those shares are anti-dilutive.

Table of Contents

11. Subsequent Events

On February 8, 2023, the Company entered into an Agreement and Plan of Merger (the “Abbott Merger Agreement”) with Abbott Laboratories, an Illinois corporation (“Abbott”), and Cobra Acquisition Co., a Delaware corporation and a direct, wholly-owned subsidiary of Abbott (“Merger Sub”). The Abbott Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Abbott Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of Abbott (the “Abbott Transaction”). At the effective time of the Abbott Transaction, each share of the Company’s common stock issued and outstanding immediately prior to the effective time, subject to certain exceptions set forth in the Abbott Merger Agreement, will automatically convert into and be exchangeable for the right to receive $20.00 per share in cash, without interest.

The boards of directors of both the Company and Abbott have unanimously approved the Abbott Merger Agreement and the Abbott Transaction. The Company’s board of directors unanimously recommended that the Company’s stockholders vote to adopt the Abbott Merger Agreement and approve the transactions contemplated thereby, including the Abbott Transaction, and directed that the adoption of the Abbott Merger Agreement be submitted to a vote of the stockholders.

The closing of the Abbott Transaction is subject to the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock to adopt the Abbott Merger Agreement, the expiration or termination of any waiting period (and extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and various other closing conditions.

The Abbott Merger Agreement includes certain termination provisions for both the Company and Abbott and provides that (i) in connection with the termination of the Abbott Merger Agreement under certain specified circumstances related to a change in the recommendation of the Company, the entry into an agreement for a superior proposal or the breach of certain of the Company’s covenants under the Abbott Merger Agreement, the Company may be required to pay Abbott a termination fee of $26,500,000, and (ii) in connection with the termination of the Abbott Merger Agreement after November 8, 2023 (or as such date might be extended under the Abbott Merger Agreement) under certain specified circumstances related to antitrust laws or due to the consummation of the Abbott Transaction being permanently enjoined under antitrust laws, Abbott may be required to pay the Company a termination fee of $26,500,000.

Additional information about the Abbott Merger Agreement and the Abbott Transaction will be set forth in the Company’s preliminary and definitive proxy statements relating to the transaction that will be filed with the SEC.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing under Item 1 of Part I of this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors” discussed in our Annual Report on Form 10-K for the year ended June 30, ~~2021~~2022 and subsequent Quarterly Reports on Form 10-Q, including in Item 1A of Part II of this Quarterly Report on Form 10-Q, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

OVERVIEW

We are a medical technology company leading the way in the effort to successfully treat patients suffering from peripheral and coronary artery diseases, including those with arterial calcium, the most difficult form of arterial disease to treat. We are committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve the lives of patients facing ~~this~~these difficult disease ~~state.~~states. We have developed patented orbital atherectomy systems (“OAS”) for both peripheral and coronary clinical applications. The primary base of our business is catheter-based platforms capable of treating a broad range of vessel sizes and plaque types, including calcified plaque, which address many of the limitations associated with other treatment alternatives.

We have observed some degree of seasonality in our business, as there tends to be a lower number of procedures that use our products during the three months ending September 30. Interventional procedure volume usually grows throughout the course of the fiscal year, with the three months ending June 30 usually representing the highest volume of cases and, therefore, the highest amount of revenue generated by us during the course of the fiscal year.

Peripheral

Our peripheral artery disease (“PAD”) products are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee, including calcified plaque, and address many of the limitations associated with other existing surgical, catheter and pharmacological treatment alternatives. The micro-invasive devices use small access sheaths that can provide procedural benefits, allow physicians to treat PAD patients in even the small and tortuous vessels located below the knee, and facilitate access through alternative sites in the ankle, foot and wrist, as well as in the groin.

The United States Food and Drug Administration (“FDA”) has granted us 510(k) clearances for our Peripheral OAS as a therapy in patients with PAD, as discussed in Item 1 of Part I of our Annual Report on Form 10-K for the year ended June 30, ~~2021.~~2022. We refer to these products in this Quarterly Report on Form 10-Q as the “Peripheral OAS.” In addition to our Peripheral OAS, we also offer support products within the peripheral space. Peripheral sales in the United States during the ~~nine~~six months ended ~~March~~December 31, 2022 represented ~~66%~~approximately 63% of revenue.

Coronary

Our coronary artery disease (“CAD”) product, the Diamondback 360 Coronary OAS (“Coronary OAS”), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application. In addition to the Coronary OAS, we also offer support products within the coronary space as we expand treatment to a broader patient population with complex coronary artery disease.

We have received premarket approval (“PMA”) from the FDA to market the Coronary OAS as a treatment for severely calcified coronary arteries. Coronary sales in the United States during the ~~nine~~six months ended ~~March~~December 31, 2022 represented approximately ~~27%~~29% of revenue.

Table of Contents

International

We serve a growing patient population globally through an expanding distribution and sales network. Sales of our approved products in Japan ~~are~~have been made through our exclusive Japan distributor, Medikit Co., Ltd. ("Medikit"). On December 13, 2022, we entered into a distribution agreement with Otsuka Medical Devices Co., Ltd. Effective February 1, 2023, upon the expiration of our distribution agreement with Medikit, Otsuka became our exclusive Japan distributor. Sales of our products in the rest of the world, which primarily includes certain countries in Southeast Asia, Europe, ~~Canada and~~Latin America, the Middle East and Canada, are made through a network of distributors and sales agents. International sales during the ~~nine~~six months ended ~~March~~December 31, 2022 represented approximately 7%8% of revenue.

Impact of COVID-19

~~Table of Contents~~

The COVID-19 pandemic in the United States and internationally has caused us to experience ongoing disruptions in the procedures using our products. Procedures have been postponed, and may continue to be postponed, as a result of reduced availability of physicians or lab space to treat patients, the lack of personal protective equipment and active virus test kits, different treatment prioritizations, increased cost pressures and burdens on the overall healthcare infrastructure that result in reallocation of resources, customer staffing shortages, and governmental guidelines and restrictions. In addition, patients have elected to defer or avoid treatment for procedures that use our products due to anxiety about the potential spread of COVID-19 in facilities. Finally, our personnel and the personnel of our distribution partners and sales agents experienced restrictions on their ability to access many customers, hospitals, labs and other medical facilities for sales activities, training and case support as they may have been deemed to be “non-essential” personnel by those facilities, and there has been a reduction in procedure activity in these accounts.

In addition to the impact on procedure volumes, we experienced other disruptions as a result of the COVID-19 ~~pandemic. For example, enrollment~~pandemic in ~~our ECLIPSE clinical trial was paused for several months. Other disruptions included restrictions on~~fiscal 2022, such as the ability of our personnel and personnel of our distribution partners to travel; delays in approvals by regulatory bodies; delays in product development efforts, which has also disrupted or delayed our ability to launch affected products; reallocation of company resources from our strategic priorities; supply chain disruptions that limited, delayed or prevented us from acquiring the components used to develop and manufacture our products or ship those products once manufactured; and decreased employee productivity. Some of these disruptions continued into the first and second quarters of fiscal 2023, although to a lesser extent than we experienced in ~~our relationships with our distributors due to~~ the ~~impact~~first and second quarters of the COVID-19 pandemic on their operations; temporary closures of our facilities; loss of employee productivity; additional government requirements to “shelter at home” or other incremental mitigation efforts that may further impact our capacity to manufacture, sell and support the use of our products; and we have experienced an increase in employee turnover, which we believe has been consistent with broader market conditions. To address the continuing uncertainties associated with the pandemic and utilize our resources more effectively, we have reduced our field clinical support and realigned a small number of our sales representatives in territories or regions where procedural volumes no longer warrant incremental case support.fiscal 2022.

Throughout the pandemic, we have operated our manufacturing facilities and continued to ship product. Most of our office-based employees have telecommuted, and our field employees have continued to support cases in clinical settings where they are able to have access. We took and continue to take several actions intended to protect the health and well-being of our workforce and our customers. We will continue to monitor developments at the local, state and national levels in order to ensure that we and our employees have current information for purposes of making decisions in the dynamic and unpredictable environment and that we comply with applicable requirements.

~~We are monitoring~~Throughout the COVID-19 pandemic, we have observed the impact from the spread of some variants, and ~~continue to track~~the fluctuations in hospitalizations resulting from these variants. ~~In particular,~~For example, there were significant disruptions in procedures ~~beginning~~that occurred in ~~early December with~~the first quarter of fiscal 2022 due to the Delta variant outbreak and in the second and third quarters of fiscal 2022 due to the Omicron variant ~~outbreak, which continued to adversely affect our business in the third quarter.~~outbreak. Many factors may increase or decrease procedure volumes, which would have an impact on our revenue and financial results, including vaccination levels and mandates, the spread of new, more viral or deadly variants of the SARS-CoV-2 virus, easing of social restrictions and government restrictions on elective and semi-elective cases, level of patient anxiety, medical facility and workforce capacity, and sales representative access to facilities to support cases. We continue to monitor the spread of variants and track hospitalizations resulting from variants of the SARS-CoV-2 virus.

The Abbott Transaction

On February 8, 2023, we entered into an Agreement and Plan of Merger (the “Abbott Merger Agreement”) with Abbott Laboratories, an Illinois corporation (“Abbott”), and Cobra Acquisition Co., a Delaware corporation and a direct, wholly-owned subsidiary of Abbott (“Merger Sub”). The Abbott Merger Agreement provides that, upon the terms and subject to the conditions set forth in such agreement, Merger Sub will merge with and into us, and we will continue as the surviving corporation and as a wholly-owned subsidiary of Abbott (the “Abbott Transaction”). At the effective time of the Abbott Transaction, each share of our common stock issued and outstanding immediately prior to the effective time, subject to certain exceptions set forth in the Abbott Merger Agreement, will automatically convert into and be exchangeable for the right to receive $20.00 per share in cash, without interest.

The boards of directors of both the Company and Abbott have unanimously approved the Abbott Merger Agreement and the Abbott Transaction. Our board of directors unanimously recommended that our stockholders vote to adopt the Abbott Merger Agreement and approve the transactions contemplated thereby, including the Abbott Transaction, and directed that the adoption of the Abbott Merger Agreement be submitted to a vote of our stockholders.

Table of Contents

The closing of the Abbott Transaction is subject to the affirmative vote of the holders of a majority of our outstanding shares of common stock to adopt the Abbott Merger Agreement, the expiration or termination of any waiting period (and extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and various other closing conditions.

The Abbott Merger Agreement includes certain termination provisions for both us and Abbott and provides that (i) in connection with the termination of the Abbott Merger Agreement under certain specified circumstances related to a change in the recommendation of the Company, the entry into an agreement for a superior proposal or the breach of certain of our covenants under the Abbott Merger Agreement, we may be required to pay Abbott a termination fee of $26,500,000, and (ii) in connection with the termination of the Abbott Merger Agreement after November 8, 2023 (or as such date might be extended under the Abbott Merger Agreement) under certain specified circumstances related to antitrust laws or due to the consummation of the Abbott Transaction being permanently enjoined under antitrust laws, Abbott may be required to pay us a termination fee of $26,500,000.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect amounts reported in those statements. Our estimates, assumptions and judgments, including those related to revenue recognition, deferred revenue and stock-based compensation, are updated as appropriate at least quarterly. We use authoritative pronouncements, our technical accounting knowledge, cumulative business experience, judgment and other factors in the selection and application of our accounting policies. While we believe that the estimates, assumptions and judgments that we use in preparing our consolidated financial statements are appropriate, these estimates, assumptions and judgments are subject to factors and uncertainties regarding their outcome. Therefore, actual results may materially differ from these estimates.

Some of our significant accounting policies require us to make subjective or complex judgments or estimates. An accounting estimate is considered to be critical if it meets both of the following criteria: (1) the estimate requires assumptions about matters that are highly uncertain at the time the accounting estimate is made, and (2) different estimates that reasonably could have been used, or changes in the estimate that are reasonably likely to occur from period to period, would have a material impact on the presentation of our financial condition, results of operations, or cash flows.

Our critical accounting policies are identified in Item 7 of Part II of our Annual Report on Form 10-K for the fiscal year ended June 30, ~~2021~~2022 under the heading “Critical Accounting Policies and Significant Judgments and Estimates.”

Table of Contents

RESULTS OF OPERATIONS

The following table sets forth our results of operations expressed as dollar amounts (in thousands) and the changes between the specified periods expressed as percent increases or decreases:


		Three Months Ended March 31,						Nine Months Ended March 31,							Three Months Ended December 31,						Six Months Ended December 31,
		2022		2021		Percent Change		2022		2021		Percent Change			2022		2021		Percent Change		2022		2021		Percent Change
Net revenues	Net revenues	$	56,221	$	63,273	(11.1)	%	$	173,726	$	187,986	(7.6)	%	Net revenues	$	61,453	$	59,135	3.9	%	$	121,126	$	117,505	3.1	%
Cost of goods sold	Cost of goods sold	14,790		14,013		5.5		47,171		40,497		16.5		Cost of goods sold	18,461		18,073		2.1		35,159		32,381		8.6
Gross profit	Gross profit	41,431		49,260		(15.9)		126,555		147,489		(14.2)		Gross profit	42,992		41,062		4.7		85,967		85,124		1.0
Expenses:	Expenses:													Expenses:
Selling, general and administrative	Selling, general and administrative	41,680		41,442		0.6		123,933		121,785		1.8		Selling, general and administrative	41,642		40,402		3.1		86,117		82,253		4.7
Research and development	Research and development	9,052		13,163		(31.2)		27,947		31,816		(12.2)		Research and development	9,533		8,873		7.4		18,589		18,895		(1.6)
Amortization of intangible assets	Amortization of intangible assets	346		304		13.8		996		912		9.2		Amortization of intangible assets	345		346		(0.3)		691		650		6.3
Total expenses	Total expenses	51,078		54,909		(7.0)		152,876		154,513		(1.1)		Total expenses	51,520		49,621		3.8		105,397		101,798		3.5
Loss from operations	Loss from operations	(9,647)		(5,649)		70.8		(26,321)		(7,024)		(274.7)		Loss from operations	(8,528)		(8,559)		(0.4)		(19,430)		(16,674)		(16.5)
Other (income) expense, net	Other (income) expense, net	(52)		292		(117.8)		660		923		(28.5)		Other (income) expense, net	(689)		345		(299.7)		(941)		712		(232.2)
Loss before income taxes	Loss before income taxes	(9,595)		(5,941)		61.5		(26,981)		(7,947)		(239.5)		Loss before income taxes	(7,839)		(8,904)		(12.0)		(18,489)		(17,386)		(6.3)
Provision for income taxes	Provision for income taxes	63		63		—		262		189		38.6		Provision for income taxes	49		63		(22.2)		30		199		(84.9)
Net loss	Net loss	$	(9,658)	$	(6,004)	60.9		$	(27,243)	$	(8,136)	(234.8)		Net loss	$	(7,888)	$	(8,967)	(12.0)		$	(18,519)	$	(17,585)	(5.3)

2022

Table of Contents

Comparison of Three Months Ended ~~March~~December 31, 2022 with Three Months Ended ~~March~~December 31, 2021

Net revenues. Net revenues ~~decreased~~increased by ~~$7.1~~$2.3 million, or ~~11.1%~~3.9%, from ~~$63.3~~$59.1 million for the three months ended ~~March~~December 31, 2021 to ~~$56.2~~$61.5 million for the three months ended ~~March~~December 31, 2022. U.S. peripheral revenues decreased ~~$4.9~~$0.6 million, or ~~11.7%~~1.6%, while U.S. coronary revenues ~~decreased $2.8~~increased $1.5 million, or ~~16.0%~~8.8%. Both therapies ~~were~~continue to be adversely affected by ~~the impact of the Omicron variant of the SARS-CoV-2 virus, which began to surge~~labor shortages and turnover in the U.S. in early December 2021. Contributing factors to the decreased case volumes from the Omicron variant were disruptions of referral patterns, deferrals of elective procedures, and staffing shortages.health care workforce. We have also been adversely affected by an increasingly competitive environment and reimbursement pressures in the office-based lab setting. Increased revenue from increased customer adoption of interventional support products ~~partially~~ offset the revenue declines from decreased case volumes, competitive pressures, and reimbursement pressures in the peripheral and coronary ~~franchise.~~franchises. International revenue was ~~$4.4~~$5.1 million for the three months ended ~~March~~December 31, 2022, compared with international revenue of $3.7 million for the three months ended ~~March~~December 31, 2021. ~~Although international sales were also impacted by the ongoing COVID-19 pandemic, increases~~Increases in international sales were driven by ~~a stronger recovery in Japan,~~ increased adoption in Europe and Canada, and the commencement of sales into other ~~territories.~~territories, as well as an increase in deferred revenue recognized. In the ~~fourth~~third quarter of fiscal ~~2022,~~2023, we expect ~~our~~to continue growing revenue, will continue to be impacted by the COVID-19 pandemic's effect on case volumes but to a lesser degree than previous quarters in fiscal 2022. Longer-term we expect revenue growth to improve when the pandemic subsides, driven by increasing the number of physicians using the ~~devices;~~devices we sell; increasing the usage per physician; ~~introducing~~the use of new and improved ~~products; generating additional clinical data;~~products, such as the Scoreflex NC scoring balloon, JADE balloons, ViperCross Microcatheters, and the 2.00 Max Crown for Peripheral OAS; and continuing expansion into new geographies, partially offset by potential decreases in average selling ~~prices.~~prices and foreign currency exchange impacts. However, ongoing factors such as staffing and supply shortages and competitive and reimbursement pressures may continue to have an adverse impact.

Cost of Goods Sold. Cost of goods sold was ~~$14.8~~$18.5 million for the three months ended ~~March~~December 31, 2022, an increase of ~~5.5%~~2.1% from ~~$14.0~~$18.1 million for the three months ended ~~March~~December 31, 2021. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. Gross margin ~~decreased~~increased to ~~73.7%~~70.0% for the three months ended ~~March~~December 31, 2022 from ~~77.9%~~69.4% for the three months ended ~~March~~December 31, 2021. The increase ~~in cost of goods sold and decrease~~ in gross margin was primarily due to ~~lower unit volumes as well as~~a $2.8 million reserve in the three months ended December 31, 2021 related to the voluntary recall of the WIRION device. Excluding this item, gross margin decreased primarily due to increased sales of lower margin ~~products.~~products, as well as increased inflationary costs and freight costs. We expect that gross margin in the ~~fourth~~third quarter of fiscal ~~2022~~2023 will be ~~approximately the same as~~similar to the three months ended ~~March~~December 31, ~~2022. We anticipate that there will be a~~2022 due to an expected increase in device sales offset by the continued shift of sales mix into interventional support products and international markets in addition to declining average selling prices, which will also impact gross margins. Quarterly margin fluctuations could also occur based on production volumes, timing of new product introductions, sales mix, pricing changes, the impact of inflation or other unanticipated circumstances.

Selling, General and Administrative Expenses. Our selling, general and administrative expenses were ~~$41.7~~$41.6 million for the three months ended ~~March~~December 31, 2022, an increase of ~~0.6%~~3.1% from ~~$41.4~~$40.4 million for the three months ended ~~March~~December 31, 2021. Selling, general and administrative expense increases were led by costs associated with new product introductions and travel-related expenditures due to resumption of live meetings and tradeshows. These increases were partially offset by reduced commission expenses due to lower sales in the current year period and a decrease in incentive compensation expense, ~~due to lower performance.~~travel-related expenditures and legal expenditures. Selling, general and administrative expenses for the three months ended ~~March~~December 31, 2022 and 2021 include ~~$3.4~~$3.0 million and ~~$3.1~~$3.6 million, respectively, for stock-based compensation. We expect our selling, general and administrative expenses for the ~~fourth~~third quarter of fiscal ~~2022~~2023 to be ~~greater~~higher than amounts incurred for the three months ended ~~March~~December 31, 2022. Quarterly fluctuations could occur based on the level of net revenue, which could be materially impacted by the factors noted above, as well as inflation.

Research and Development Expenses. Research and development expenses increased by 7.4%, from $8.9 million for the three months ended December 31, 2021 to $9.5 million for the three months ended December 31, 2022. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and expanded product offerings, including our percutaneous ventricular assist device, and to clinical trials. The increase was primarily due to increased costs on the ECLIPSE clinical trial, initiation of the Japan Kaizen clinical study and timing of costs associated with the development activities of our percutaneous ventricular assist device. We expect an increase in research and development expense in the third quarter of fiscal 2023 from what we incurred during the three months ended December 31, 2022. Quarterly fluctuations could occur based on the number of projects and studies, the progress of such projects and studies, the rate of study enrollment, the impact of inflation, acquisitions of in process research and development and possible charges in connection with those acquisitions, and the timing of expenditures.

Table of Contents

Comparison of Six Months Ended December 31, 2022 with Six Months Ended December 31, 2021

Net revenues. Net revenues increased by $3.6 million, or 3.1%, from $117.5 million for the six months ended December 31, 2021 to $121.1 million for the six months ended December 31, 2022. U.S. peripheral revenues decreased $0.8 million, or 1.1% and U.S. coronary revenues increased $1.7 million, or 5.1%. Both therapies continue to be adversely affected by labor shortages and turnover in the health care workforce. We have also been adversely affected by an increasingly competitive environment and reimbursement pressures in the office-based lab setting. Increased revenue from increased customer adoption of interventional support products offset the revenue declines from decreased case volumes, competitive pressures, and reimbursement pressures in the peripheral and coronary franchises. International revenue was $9.8 million for the six months ended December 31, 2022, compared with international revenue of $7.0 million for the six months ended December 31, 2021. Increases in international sales were driven by increased adoption in Europe and Canada, and the commencement of sales into other territories, as well as an increase in deferred revenue recognized.

Cost of Goods Sold. Cost of goods sold was $35.2 million for the six months ended December 31, 2022, an increase of 8.6% from $32.4 million for the six months ended December 31, 2021. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. Gross margin decreased to 71.0% for the six months ended December 31, 2022 from 72.4% for the six months ended December 31, 2021. Excluding the $2.8 million reserve in the six months ended December 31, 2021 related to the voluntary recall of the WIRION device, the increase in cost of goods sold and decrease in gross margin were primarily due to increased sales of lower margin products, as well as increased inflationary costs and freight costs.

Selling, General and Administrative Expenses. Our selling, general and administrative expenses were $86.1 million for the six months ended December 31, 2022, an increase of 4.7% from $82.3 million for the six months ended December 31, 2021. Selling, general and administrative expense increases were led by costs associated with incentive compensation expense and travel-related expenditures. These increases were partially offset by lower stock compensation. Selling, general and administrative expenses for the six months ended December 31, 2022 and 2021 include $6.8 million and $8.1 million, respectively, for stock-based compensation.

Research and Development Expenses. Research and development expenses decreased by ~~31.2%~~1.6%, from ~~$13.2~~$18.9 million for the ~~three~~six months ended ~~March~~December 31, 2021 to ~~$9.1~~$18.6 million for the ~~three~~six months ended ~~March~~December 31, 2022. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and expanded product offerings, including our percutaneous ventricular assist device, and to clinical trials. The decrease was primarily due to in process research and development ("IPR&D") charges incurred with our asset acquisition of a line of peripheral microcatheters in the three months ended March 31, 2021. We expect an increase in research and development expense in the fourth quarter of fiscal 2022 from what we incurred during the three months ended March 31, 2022. Quarterly fluctuations could occur based on the number of projects and studies, the progress of such projects and studies, the rate of study enrollment, acquisitions of IPR&D and possible charges in connection with those acquisitions, and the timing of ~~expenditures.~~

international commercialization expenses and project spend.

2124

Table of Contents

~~Comparison of Nine Months Ended March 31, 2022 with Nine Months Ended March 31, 2021~~

~~Net revenues.~~ Net revenues decreased by $14.3 million, or 7.6%, from $188.0 million for the nine months ended March 31, 2021 to $173.7 million for the nine months ended March 31, 2022. U.S. peripheral revenues decreased $14.1 million, or 10.9% and U.S. coronary revenues decreased $3.9 million, or 7.5%. Both therapies were adversely affected by the impact of the Delta and Omicron variants of the SARS-CoV-2 virus, especially within the hospital setting. Contributing factors to the decreased case volumes from the Delta and Omicron variants were disruptions of referral patterns, deferrals of elective procedures, staffing shortages and heightened summer seasonality in the quarter ended September 30, 2021. We have also been adversely affected by an increasingly competitive environment and reimbursement pressures in the office-based lab setting. Increased revenue from new product launches and increased customer adoption of interventional support products partially offset the revenue declines from decreased case volumes in the peripheral and coronary franchise. International revenue was $11.4 million for the nine months ended March 31, 2022, compared with international revenue of $7.7 million for the nine months ended March 31, 2021. Although international sales were also impacted by the ongoing COVID-19 pandemic, increases in international sales were driven by Coronary OAS sales in Europe, a stronger recovery in Japan, and the commencement of sales into other territories.

~~Cost of Goods Sold.~~ Cost of goods sold was $47.2 million for the nine months ended March 31, 2022, an increase of 16.5% from $40.5 million for the nine months ended March 31, 2021. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. Gross margin decreased to 72.8% for the nine months ended March 31, 2022 from 78.5% for the nine months ended March 31, 2021. The increase in cost of goods sold and decrease in gross margin were primarily due to the $2.8 million reserve related to the voluntary recall of the WIRION device, lower unit volumes, as well as increased sales of lower margin products.

~~Selling, General and Administrative Expenses.~~ Our selling, general and administrative expenses were $123.9 million for the nine months ended March 31, 2022, an increase of 1.8% from $121.8 million for the nine months ended March 31, 2021. Selling, general and administrative expense increases were led by costs associated with new product introductions and the resumption of travel-related expenditures due to increased live meetings and tradeshows, in addition to annual salary increases for our employees. These increases were partially offset by reduced commission expenses due to lower sales in the current year period and a decrease in incentive compensation expense due to lower performance. Selling, general and administrative expenses for the nine months ended March 31, 2022 and 2021 include $11.5 million and $10.5 million, respectively, for stock-based compensation.

~~Research and Development Expenses.~~ Research and development expenses decreased by 12.2%, from $31.8 million for the nine months ended March 31, 2021 to $27.9 million for the nine months ended March 31, 2022. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and expanded product offerings, including our percutaneous ventricular assist device, and to clinical trials. The decrease was primarily due to IPR&D charges incurred with our asset acquisition of a line of peripheral microcatheters in the nine months ended March 31, 2021.

LIQUIDITY AND CAPITAL RESOURCES

We had cash, cash equivalents and highly liquid marketable securities of ~~$172.1~~$132.0 million and ~~$207.0~~$159.8 million at ~~March~~December 31, 2022 and June 30, ~~2021,~~2022, respectively. As of ~~March~~December 31, 2022, we had an accumulated deficit of ~~$413.9~~$443.4 million. We have historically funded our operating losses primarily from the issuance of common and preferred stock, convertible promissory notes, and debt.

A summary of our cash flow activities (in thousands) is as follows:


		Nine Months Ended					Six Months Ended
		March 31,					December 31,
		2022		2021			2022		2021
Net cash used in operating activities	Net cash used in operating activities	$	(14,443)	$	(2,420)	Net cash used in operating activities	$	(17,200)	$	(12,315)
Net cash provided by (used in) investing activities		14,484		(104,878)
Net cash used in financing activities		(4,158)		(2,832)
Net cash provided by investing activities						Net cash provided by investing activities	10,474		11,109
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	145		(3,999)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	$	(4,117)	$	(110,130)	Net change in cash and cash equivalents	$	(6,581)	$	(5,205)

~~Table of Contents~~

Changes in Liquidity

Operating Activities

Net cash used in operating activities was ~~$14.4~~$17.2 million for the ~~nine~~six months ended ~~March~~December 31, 2022, primarily due to the net loss of ~~$27.2~~$18.5 million, and ~~$5.6~~$8.5 million relating to changes in working capital as a result of the payout of annual bonuses and commissions, increased uses of cash to build inventory as we diversify our product offerings, partially offset by non-cash expenditures for the six months ended December 31, 2022.

Net cash used in operating activities was $12.3 million for the six months ended December 31, 2021, primarily due to the net loss of $17.6 million, and $8.0 million relating to changes in working capital as a result of the payout of annual bonuses and commissions, partially offset by non-cash expenditures for the ~~nine~~six months ended ~~March~~December 31, ~~2022.~~

Net cash used in operating activities was $2.4 million for the nine months ended March 31, 2021, primarily due to the net loss of $8.1 million, and $14.4 million relating to changes in working capital as a result of the recovery from the initial wave of the COVID-19 pandemic in our business, partially offset by non-cash expenditures for the nine months ended March 31, 2022.2021.

Investing Activities

Net cash provided by investing activities was ~~$14.5~~$10.5 million for the ~~nine~~six months ended ~~March~~December 31, 2022, as maturities and sales of marketable securities exceeded marketable security purchases. These amounts were partially offset by additional payments relating to strategic investments and capital expenditures as we continue to grow our business.

Net cash provided by investing activities was $11.1 million for the six months ended December 31, 2021, as maturities and sales of marketable securities exceeded marketable security purchases during this period. These amounts were partially offset by a product acquisition of peripheral microcatheters, additional payments relating to strategic investments and capital expenditures as we continue to grow our business.

Financing Activities

Net cash ~~used in investing~~provided by financing activities was ~~$104.9~~$0.1 million for the ~~nine~~six months ended ~~March~~December 31, ~~2021,~~2022, primarily due to ~~investing cash~~proceeds from our June 2020 equity offering into marketable securities. We also deployed cash into strategic investments, product acquisitions and capital expenditures as we continue to grow our business. These uses of cash wereemployee stock purchases, partially offset by ~~maturities and sales~~payment of ~~marketable securities.~~

~~Financing Activities~~payroll taxes on the employee vesting of stock awards.

Net cash used in financing activities was ~~$4.2 million and $2.8~~$4.0 million for the ~~nine~~six months ended ~~March~~December 31, ~~2022 and~~ 2021, ~~respectively,~~ primarily due to the payment of payroll taxes on the employee vesting of stock awards, partially offset by proceeds from employee stock purchases.

Our future liquidity and capital requirements will be influenced by numerous factors, including whether we timely consummate the Abbott Transaction, the extent and duration of future operating losses, the level and timing of future sales and expenditures, the results and scope of ongoing research and product development programs, working capital required to support our business operations, the receipt of and time required to obtain regulatory clearances and approvals, our sales and marketing programs, the continuing acceptance of our products in the marketplace, competing technologies, market and regulatory developments, ongoing facility requirements, potential strategic transactions (including the potential acquisition of, or investments in, businesses, technologies and products), international expansion, the existence, defense and resolution of legal proceedings, and

Table of Contents

the severity and duration of the COVID-19 pandemic. As discussed in the "Overview" above, the total impact of disruptions from COVID-19 has had a material impact on our financial condition and results of operations, but ~~once~~as the pandemic subsides, we expect our U.S. business to improve. We will continue to closely monitor our liquidity and capital resources through the disruption caused by COVID-19 and will continue to evaluate our financial position to assess additional spending reductions and our liquidity needs. As of ~~March~~December 31, 2022, we believe our current cash, cash equivalents and marketable securities will be sufficient to fund working capital requirements, including open purchase commitments, capital expenditures and operations for the foreseeable future, including at least the next twelve months, as well as to fund payments under our lease agreements, payments under development agreements, and ~~future payments relating to our asset acquisition of the WIRION embolic protection system.~~funding commitments under loan agreements. If needed, we have the ability to borrow under our senior, secured revolving credit ~~facility.~~facility, which we intend to extend. We will also consider other options for potential future financings to fund our longer-term objectives. We intend to retain any future earnings to support operations and to finance the growth and development of our business. We do not anticipate paying any dividends in the foreseeable future.

~~Table of Contents~~

Facility Sale and Lease

On December 29, 2016, we entered into a Purchase and Sale Agreement, as subsequently amended (collectively, the “Sale Agreement”), with Krishna Holdings, LLC (“Krishna”), providing for the sale to Krishna of our headquarters facility in St. Paul, Minnesota (the “Facility”) for a cash purchase price of $21.5 million. On March 30, 2017, the sale of the Facility under the Sale Agreement closed. We received proceeds of approximately $20.9 million ($21.5 million less $556,000 of transaction expenses). In connection with the closing of the facility sale, we entered into a Lease Agreement (the “Lease Agreement”) with Krishna Holdings, LLC, Apex Holdings, LLC, Kashi Associates, LLC, Keva Holdings, LLC, S&V Ventures, LLC, Polo Group LLC, SPAV Holdings LLC, Star Associates LLC, and The Global Villa, LLC. The Lease Agreement has an initial term of fifteen years, with four consecutive renewal options of five years each, with a base annual rent in the first year of $1.6 million and annual escalations of 3%. See Note 65 to our Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q for additional discussion.

Revolving Credit Facility

In March 2017, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). In March 2020, we entered into the First Amendment to the Loan Agreement (the "Amendment"). The Amendment extended the maturity date of the Loan Agreement by two years, to March 31, 2022, and increased the maximum amount available under the senior, secured revolving credit facility (the "Revolver") to $50.0 million (the “Maximum Dollar Amount”). In March 2022, the Company entered into the Second Amendment to the Loan Agreement (the "Second Amendment"). The Second Amendment extended the maturity date of the Loan Agreement by one year, to March 31, 2023. We intend to seek an additional extension of the Loan Agreement.

Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.75%. Interest on borrowings is due monthly and the principal balance is due at maturity. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. We will incur a fee equal to 1.5% of the Maximum Dollar Amount upon termination of the Loan Agreement, as amended by the Second Amendment (the "Amended Loan Agreement"), or the Revolver for any reason prior to the date that is fifteen days prior to the maturity date, unless refinanced with SVB.

Our obligations under the Amended Loan Agreement are secured by certain of our assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include our intellectual property, but we agreed not to encumber our intellectual property without the consent of SVB. The Amended Loan Agreement contains customary covenants limiting our ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of our business. In addition, the Amended Loan Agreement contains financial covenants requiring us to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10.0 million or (ii) minimum trailing three-month Adjusted EBITDA (as defined in the Amended Loan Agreement) of $1.0 million. If we do not comply with the various covenants under the Amended Loan Agreement or an event of default under the Amended Loan Agreement occurs, such as a material adverse change, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights and the other terms and conditions of the Amended Loan Agreement, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral.

Table of Contents

We are required to pay a fee equal to 0.15% per annum on the unused portion of the Revolver, payable quarterly in arrears. We are not obligated to draw any funds under the Revolver and have not done so under the Revolver since entering into the Loan Agreement. No amounts were outstanding as of ~~March~~December 31, ~~2022 and we currently do not have plans to borrow under the Amended Loan Agreement.~~2022.

NON-GAAP FINANCIAL INFORMATION

To supplement our condensed consolidated financial statements prepared in accordance with GAAP, our management uses a non-GAAP financial measure referred to as “Adjusted EBITDA.” Reconciliations of this non-GAAP measure to the most comparable U.S. GAAP measure for the respective periods can be found in the following table. In addition, an explanation of the manner in which our management uses this measure to conduct and evaluate our business, the economic substance behind our management's decision to use this measure, the substantive reasons why our management believes that this measure provides useful information to investors, the material limitations associated with the use of this measure and the manner in which our management compensates for those limitations is included following the reconciliation table.

~~Table of Contents~~


		Three Months Ended				Nine Months Ended					Three Months Ended				Six Months Ended
		March 31,				March 31,					December 31,				December 31,
		2022		2021		2022		2021			2022		2021		2022		2021
Net loss	Net loss	$	(9,658)	$	(6,004)	$	(27,243)	$	(8,136)	Net loss	$	(7,888)	$	(8,967)	$	(18,519)	$	(17,585)
Less: Other (income) expense, net	Less: Other (income) expense, net	(52)		292		660		923		Less: Other (income) expense, net	(689)		345		(941)		712
Less: Provision for income taxes	Less: Provision for income taxes	63		63		262		189		Less: Provision for income taxes	49		63		30		199
Loss from operations	Loss from operations	(9,647)		(5,649)		(26,321)		(7,024)		Loss from operations	(8,528)		(8,559)		(19,430)		(16,674)
Add: Stock-based compensation	Add: Stock-based compensation	3,892		3,704		13,804		12,488		Add: Stock-based compensation	3,547		4,240		7,985		9,912
Add: Depreciation and amortization	Add: Depreciation and amortization	1,286		1,056		3,831		3,143		Add: Depreciation and amortization	1,268		1,287		2,488		2,545
Adjusted EBITDA	Adjusted EBITDA	$	(4,469)	$	(889)	$	(8,686)	$	8,607	Adjusted EBITDA	$	(3,713)	$	(3,032)	$	(8,957)	$	(4,217)

Adjusted EBITDA decreased for the three and ~~nine~~six months ended ~~March~~December 31, 2022 as compared to the three and ~~nine~~six months ended ~~March~~December 31, 2021 primarily due to a greater loss from operations and lower stock compensation expense in the current year.

Use and Economic Substance of Non-GAAP Financial Measures Used and Usefulness of Such Non-GAAP Financial Measures to Investors

We use Adjusted EBITDA as a supplemental measure of performance and believe this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense, and stock-based compensation. Our management uses Adjusted EBITDA to analyze the underlying trends in our business, assess the performance of our core operations, establish operational goals and forecasts that are used to allocate resources and evaluate our performance period over period and in relation to our competitors’ operating results. Additionally, our management is partially evaluated on the basis of Adjusted EBITDA when determining achievement of their incentive compensation performance targets. Management does not use this Adjusted EBITDA measure as a liquidity measure or in the calculation of our financial covenants under the revolving credit facility with Silicon Valley Bank.

We believe that presenting Adjusted EBITDA provides investors greater transparency to the information used by our management for its financial and operational decision-making and allows investors to see our results “through the eyes” of management. We also believe that providing this information better enables our investors to understand our operating performance and evaluate the methodology used by our management to evaluate and measure such performance.

The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items:

•Stock-based compensation. We exclude stock-based compensation expense from our non-GAAP financial measures primarily because such expense, while constituting an ongoing and recurring expense, is not an expense that requires cash settlement.

•Depreciation and amortization expense. We exclude depreciation and amortization expense from our non-GAAP financial measures primarily because such expenses, while constituting ongoing and recurring expenses, are not

Table of Contents

expenses that require cash settlement and are not used by our management to assess the core profitability of our business operations.

Our management also believes that excluding these above items from our non-GAAP results is useful to investors to understand our operational performance, liquidity and ability to make additional investments in our company.

Beginning with the quarter ended March 31, 2022, following correspondence from the staff of the U.S. Securities and Exchange Commission, we no longer exclude IPR&D charges incurred in connection with asset acquisitions from Adjusted EBITDA or any other reported non-GAAP financial measures. For purposes of comparability, we have revised the reconciliation table above for three and nine months ended March 31, 2021 to reflect this approach.

~~Table of Contents~~

Material Limitations Associated with the Use of Non-GAAP Financial Measures and Manner in which We Compensate for these Limitations

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Some of the limitations associated with our use of these non-GAAP financial measures are:

•Items such as stock-based compensation do not directly affect our cash flow position; however, such items reflect economic costs to us and are not reflected in our Adjusted EBITDA, and therefore these non-GAAP measures do not reflect the full economic effect of these items.

•Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

•Our management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures we use. We compensate for these limitations by relying primarily upon our GAAP results and using non-GAAP financial measures only supplementally.

We provide detailed reconciliations of each non-GAAP measure to its most directly comparable GAAP measure. We encourage investors to review these reconciliations. We qualify our use of non-GAAP financial measures with cautionary statements as set forth above.

INFLATION

We do not believe that inflation had a material impact on our business and operating results during the periods presented.

RECENT ACCOUNTING PRONOUNCEMENTS

For a description of recent accounting pronouncements, see Note 1 to the Consolidated Financial Statements included in Item 8 of Part II of our Annual Report on Form 10-K for the year ended June 30, ~~2021.~~2022.

PRIVATE SECURITIES LITIGATION REFORM ACT

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Such “forward-looking” information is included in this Quarterly Report on Form 10-Q and in other materials filed or to be filed by us with the SEC (as well as information included in oral statements or other written statements made or to be made by us). Forward-looking statements include all statements based on future expectations. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, including, but not limited to, (i) our expectations regarding the impact of the COVID-19 pandemic on our operations; (ii) our expectation of continued sales of our products internationally, including the specific products to be sold, the territories in which such products will be sold, the timing of such sales, and whether such sales will be through distributors or directly by us; (iii) seasonality in our business; (iv) our expectation that ~~our~~we will grow revenue ~~will continue to be impacted by~~in the ~~COVID-19 pandemic during our fourth~~third quarter ~~but to a lesser extent than prior quarters in~~of fiscal ~~2022, and that our revenue growth will improve;~~2023; (v) our expectation that we will incur selling, general and administrative expenses in the ~~fourth~~third quarter of fiscal ~~2022~~2023 that are higher than the amounts incurred in the three months ended ~~March~~December 31, 2022; (vi) our expectation that gross margin in the ~~fourth~~third quarter of fiscal ~~2022~~2023 will be similar to the gross margin in the three months ended ~~March~~December 31, 2022; (vii) our expectation that we will incur research and development expenses in the ~~fourth~~third quarter of fiscal ~~2022~~2023 that are higher than the amounts incurred in the three months ended ~~March~~December 31, 2022; (viii) our belief that our current cash and cash equivalents will be sufficient to fund working capital requirements, capital expenditures and operations for the foreseeable future, as well as to fund certain other anticipated ~~expenses;~~expenses, and our consideration of future financing options; (ix) our intention to retain any future earnings to support operations and to finance the growth and development of our business; (x) our dividend expectations; (xi) our ~~plan not~~intention to ~~borrow under~~extend our loan and security agreement; ~~and~~ (xii) the anticipated impact of adoption of recent accounting pronouncements on our financial ~~statements.~~statements; and (xiii) the proposed transaction with Abbott.

Table of Contents

In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on their interpretation of currently available information.

~~Table of Contents~~

These statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These factors include the ongoing COVID-19 pandemic and the impact and scope thereof on us, our distribution partners, the supply chain and physicians and facilities, including government actions related to the COVID-19 outbreak, material delays and cancellations of procedures, delayed spending by healthcare providers, and distributor and supply chain disruptions; regulatory developments, clearances and approvals; approval of our products for distribution outside of the United States; approval of products for reimbursement and the level of reimbursement in the U.S.~~, Japan~~ and ~~other~~ foreign countries; dependence on market growth; agreements with third parties to sell their products; the ability of us and our distribution partners to successfully launch our products outside of the United States; our ability to maintain third-party supplier relationships and renew existing purchase agreements; our ability to maintain our relationships and agreements with distribution partners; the experience of physicians regarding the effectiveness and reliability of the products we sell; the reluctance of physicians, hospitals and other organizations to accept new products; the potential for unanticipated delays in enrolling medical centers and patients for clinical trials; actual clinical trial and study results; the impact of competitive products and pricing; our ability to comply with the financial covenants in our loan and security agreement and to make payments under and comply with the lease agreement for our corporate headquarters; unanticipated developments affecting our estimates regarding expenses, future revenues and capital requirements; the difficulty of successfully managing operating costs; our ability to manage our sales force strategy; actual research and development efforts and needs, including the timing of product development programs; successful collaboration on the development of new products; ~~including~~ agreements with development partners, advisors and other third parties; the ability of us and these third parties to meet ~~development,~~developmental, contractual and other milestones; contractual rights and obligations; technical challenges; our ability to obtain and maintain intellectual property protection for product candidates; fluctuations in results and expenses based on new product introductions, sales mix, unanticipated warranty claims, and the timing of project expenditures; our ability to manage costs; our actual financial resources and our ability to obtain additional financing; investigations or litigation threatened or initiated against us; court rulings and future actions by the FDA and other regulatory bodies; international trade developments; the effects of hurricanes, flooding, and other natural disasters on our business; the impact of federal corporate tax reform on our business, operations and financial statements; shutdowns of the U.S. federal government; the potential impact of any future strategic transactions; our and Abbott’s ability to consummate the proposed transaction on a timely basis or at all; our and Abbott’s ability to satisfy the conditions precedent to consummation of the proposed transaction, including the ability to secure the applicable regulatory approvals on the terms expected, at all or in a timely manner; the effect of the announcement of the proposed transaction on our ability to retain and hire key personnel and maintain relationships with our key business partners and customers, and others with whom we do business, or on our operating results and businesses generally; the response of competitors to the proposed Abbott transaction; risks associated with the disruption of our management's attention from ongoing business operations due to the proposed Abbott transaction; significant costs associated with the proposed transaction; potential litigation relating to the proposed Abbott transaction; restrictions during the pendency of the proposed Abbott transaction that may impact our ability to conduct our business; and general economic conditions.

These and additional risks and uncertainties are described more fully in our Annual Report on Form 10-K for the year ended June 30, ~~2021~~2022 and subsequent Quarterly Reports on Form 10-Q, including in Item 1A of Part II of this Quarterly Report on Form 10-Q. Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis and retrieval system (EDGAR) at www.sec.gov.

You should read these risk factors and the other cautionary statements made in this Quarterly Report on Form 10-Q as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report on Form 10-Q. We cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should read this Quarterly Report on Form 10-Q completely. Other than as required by law, we undertake no obligation to update these forward-looking statements, even though our situation may change in the future.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Other than the negative impact the COVID-19 pandemic has had and will continue to have on our business and results of operations as discussed elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes in our primary risk exposures or management of market risks from those disclosed in our Annual Report on Form 10-K for the year ended June 30, ~~2021.~~2022.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, are responsible for establishing and maintaining our disclosure controls and procedures. The Certifying Officers have reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of ~~March~~December 31, 2022. Based on that review and evaluation, which included inquiries made to certain other of our employees, the Certifying Officers have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures, as designed and implemented, are effective.

~~Table of Contents~~

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended ~~March~~December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, including the important information in the section entitled “Private Securities Litigation Reform Act,” you should carefully consider the “Risk Factors” in our Annual Report on Form 10-K for the year ended June 30, ~~2021~~2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report on Form 10-Q and materially adversely affect our business, financial condition and/or future operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also might materially adversely affect our business, financial condition and/or operating results. In addition, you should consider the following risk factors:

The completion of the Abbott Transaction is subject to a number of conditions, many of which are largely outside of the parties’ control, and, if these conditions are not satisfied or waived on a timely basis, the Abbott Merger Agreement may be terminated and the Abbott Transaction may not be completed.

The Abbott Transaction is subject to various closing conditions, including:

•the affirmative vote of the holders of a majority of the outstanding shares of Common Stock to adopt the Abbott Merger Agreement;

•the absence of any law or order restraining or otherwise prohibiting the Abbott Transaction;

•any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 must have expired or been terminated and all consents, approvals, authorizations or filings with any governmental authority pursuant to any other applicable competition law or foreign investment law in connection with the Abbott Transaction and the transactions contemplated by the Abbott Merger Agreement, or that are reasonably determined by Abbott to be applicable, must have been obtained, in each case, without the imposition of any Burdensome Condition (as defined in the Merger Agreement), except, in each case, as may be consented to by Abbott in its sole and absolute discretion;

•subject to specific standards, the accuracy of the representations and warranties of the other party or parties;

•the performance or compliance in all material respects by the other party or parties of such party’s or parties’ covenants, obligations, and agreements under the Abbott Merger Agreement; and

•with respect to Abbott’s and Merger Sub’s obligations to consummate the Abbott Transaction, (A) the absence of a Material Adverse Effect (as defined in the Abbott Merger Agreement) and the absence of any changes having occurred that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and (B) the absence of any pending or threatened proceeding from a governmental authority (1) seeking to restrain or prohibit the Abbott Transaction, (2) seeking from any party to the transaction damages that are material to us and our subsidiaries, taken as whole, (3) seeking to impose any Burdensome Condition (as defined in the Abbott Merger Agreement), or (4)

Table of Contents

otherwise inquiring into the compliance of the Abbott Transaction with applicable competition laws or foreign investment laws.

The failure to satisfy all of the required conditions could delay the completion of the Abbott Transaction by a significant period of time or prevent it from closing. Any delay in completing the Abbott Transaction could cause the parties to not realize some or all of the benefits that are expected to be achieved if the Abbott Transaction is successfully completed within the expected timeframe. There can be no assurance that the conditions to closing of the Abbott Transaction will be satisfied or waived or that the Abbott Transaction will be completed within the expected timeframe, or at all.

Failure to complete the Abbott Transaction could materially adversely affect the price of our common stock, as well as our future business and financial results.

There can be no assurance that the conditions to the closing of the Abbott Transaction will be satisfied or waived or that the Abbott Transaction will be completed in timely manner, or at all. If the Abbott Transaction is not completed within the expected timeframe or at all, our ongoing business could be materially adversely affected and we will be subject to a variety of additional risks and possible consequences associated with the failure to complete the Abbott Transaction, including the following:

•upon termination of the Abbott Merger Agreement under specified circumstances, we may be required to pay Abbott a termination fee of $26,500,000;

•we have incurred and will continue to incur substantial transaction costs, including legal, accounting, financial advisor, filing, printing and mailing fees, regardless of whether the Abbott Transaction closes;

•under the Abbott Merger Agreement, we are subject to restrictions on the conduct of our business prior to the closing of the Abbott Transaction, which may adversely affect our ability to execute our business strategies; and

•the proposed Abbott Transaction, whether or not it closes, will significantly divert the attention of certain of our management and other key employees from ongoing business activities, including the pursuit of other opportunities that could be beneficial to us as an independent company.

If the Abbott Transaction is not completed, these risks could materially affect our business and financial results and the trading price of our common stock, including to the extent that the market price of our common stock is positively affected by a market assumption that the Abbott Transaction will be completed.

While the Abbott Transaction is pending, we will be subject to several business uncertainties and contractual restrictions that could adversely affect our business and operations.

In connection with the pending Abbott Transaction, some customers, vendors, distributors or other third parties with which we have important business relationships may react unfavorably, including by delaying or deferring decisions concerning their business relationships or transactions with us, which could adversely affect our revenues, earnings, funds from operations, cash flows, expenses and prospects, regardless of whether the Abbott Transaction is completed. In addition, due to restrictions in the Abbott Merger Agreement on the conduct of our business prior to completing the Abbott Transaction, we are unable, without Abbott’s prior written consent, during the pendency of the Abbott Transaction, to pursue strategic transactions, undertake significant capital projects, undertake certain significant financing transactions and otherwise pursue other actions, even if such actions would prove beneficial, and may cause us to forego certain opportunities we might otherwise wish to pursue. Abbott may withhold its consent of these items for any reason. In addition, the pendency of the Abbott Transaction may make it more difficult for us to effectively retain and incentivize key personnel and may cause distractions from our strategy and day-to-day operations for our current employees and management.

We will incur substantial transaction fees and costs in connection with the Abbott Transaction that could adversely affect our business and operations if the Abbott Transaction is not completed.

We have incurred and expects to incur significant non-recurring transaction fees, which include legal and advisory fees and substantial costs associated with completing the Abbott Transaction, and which could adversely affect our business operations and cash position if the Abbott Transaction is not completed.

The termination fee and restrictions on solicitation contained in the Abbott Merger Agreement may discourage other companies from trying to acquire us while the Abbott Transaction is pending.

The Abbott Merger Agreement prohibits us from soliciting, initiating, knowingly encouraging or knowingly facilitating any competing acquisition proposals, subject to certain limited exceptions. The Abbott Merger Agreement also contains certain

Table of Contents

termination rights, including, but not limited to, our right to terminate the Abbott Merger Agreement to accept a Superior Proposal (as defined in the Abbott Merger Agreement), subject to and in accordance with the terms and conditions of the Abbott Merger Agreement. The Abbott Merger Agreement further provides that, upon our termination of the Abbott Merger Agreement to enter into an alternative acquisition agreement that is the subject of a Superior Proposal, we will be required to pay Abbott a termination fee of $26,500,000 in cash. The termination fees and restrictions in the Abbott Merger Agreement relating to acquisition proposals by third parties, including with respect to the process such third parties would need to follow, could discourage other companies from trying to acquire us, even though those other companies might be willing to offer greater value to our stockholders than they will receive in the Abbott Transaction.

Litigation against us, Abbott, or the members of their respective boards could prevent or delay the completion of the Abbott Transaction or result in the payment of damages following completion of the Abbott Transaction.

It is possible that lawsuits may be filed by certain of our stockholders challenging the Abbott Transaction. The outcome of such lawsuits cannot be assured, including the amount of costs associated with defending these claims or any other liabilities that may be incurred in connection with the litigation of these claims. If a plaintiff in any such lawsuits is successful in obtaining an injunction prohibiting the parties from completing the Abbott Transaction, such injunction may delay the consummation of the Abbott Transaction in the expected timeframe, or may prevent the Abbott Transaction from being consummated at all. Whether or not any such plaintiff’s claim is successful, this type of litigation can result in significant costs and divert management’s attention and resources from the closing of the Abbott Transaction and ongoing business activities, which could adversely affect our operations.

Uncertainty about the Abbott Transaction may adversely affect the relationships between us and our customers, suppliers, distributors, business partners, vendors and employees, whether or not the Abbott Transaction is completed.

In response to the announcement of the Abbott Transaction, existing or prospective customers, suppliers, distributors, business partners, vendors and other of our third party relationships may delay, defer or cease providing goods or services or continuing work on strategic programs, delay or defer other decisions concerning our business, refuse to extend credit to us or extend the terms of material contracts, or otherwise seek to change the terms on which they do business with us. Any such delays or changes to terms could materially adversely harm our business.

In addition, as a result of the Abbott Transaction, current and prospective employees could experience uncertainty about their future with us. These uncertainties may impair our ability to retain, recruit or motivate key management and technical, manufacturing, and other personnel.

If the Abbott Merger is not consummated by November 8, 2023 (with is subject to up to extensions of up to three successive 90-day periods by Abbott in certain circumstances), either we or Abbott may terminate the Abbott Merger Agreement, subject to certain exceptions. In the event the Abbott Merger Agreement is terminated by either party, we will have incurred significant costs and will have diverted significant management focus and resources from other strategic opportunities and ongoing business activities without realizing the anticipated benefits of the Abbott Transaction, which could be materially adverse to us.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Company Repurchases of Equity Securities

The following table presents information with respect to purchases made by us of our common stock during the ~~third~~second quarter of fiscal ~~2022:~~2023:
Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares that May Yet Be Purchased under the Plan or Programs
January 1 to January 31, 2022 — $ — N/A N/A
February 1 to February 28, 2022(1)
5,386 19.80 N/A N/A
March 1 to March 31, 2022 — — N/A N/A
5,386 $ 19.80


	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased under the Plan or Programs
October 1 to October 31, 2022(1)	—	$	—	N/A	N/A
November 1 to November 30, 2022(1)	1,569	14.67		N/A	N/A
December 1 to December 31, 2022	—	—		N/A	N/A
	1,569	$	14.67

(1) Comprised of shares withheld pursuant to the terms of restricted stock awards under our stock-based compensation plans to offset tax withholding obligations that occur upon vesting and release of shares. The value of the shares withheld is the closing price of our common stock on the date the relevant transaction occurs.

Table of Contents

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

2834

Table of Contents

ITEM 6. EXHIBITS


Exhibit No.						Description






















10.1†*2.1						~~Fiscal 2022 Second Half Bonus Plan.~~Agreement and Plan of Merger, dated as of February 8, 2023, by and among the Company, Abbott Laboratories, and Cobra Acquisition Co. (previously filed with the SEC as an Exhibit to and incorporated herein by reference from the Company’s Current Report on Form 8-K filed February 9, 2023).

10.2†10.1†						~~Separation~~Loan Agreement, dated ~~March 3,~~as of December 30, 2022, by and between the Company and ~~Ryan Egeland.~~Chansu Vascular Technologies, LLC.

10.310.2†						~~Second Amendment to Loan~~First Amended and ~~Security~~Restated Acquisition Option Agreement, dated as of December 30, 2022, by and among the Company, Chansu Vascular Technologies, LLC, and the members of Chansu Vascular Technologies, LLC.

10.3*†						Product Development Agreement, dated as of January 2 9 , 202 1 , by and between ~~Cardiovascular Systems, Inc.~~the Company and ~~Silicon Valley Bank, dated March 29, 2022.~~Chansu Vascular Technologies, LLC.

31.1*						Certification of Chairman, President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*						Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**						Certification of Chairman, President and Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**						Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*						Financial statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended ~~March~~December 31, 2022, formatted in Inline XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Changes in Stockholders’ Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Financial Statements.

104*						Cover page interactive data file (formatted in Inline XBRL and contained in Exhibit 101).

_______________________

* Filed herewith.

** Furnished herewith.

† ~~Compensatory plan~~Exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted exhibit or ~~agreement.~~schedule will be furnished supplementally to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any document so furnished.

2935

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


Dated: ~~May 5, 2022~~February 9, 2023		CARDIOVASCULAR SYSTEMS, INC.

	By	/s/ Scott R. Ward
		Scott R. Ward
		Chairman, President and Chief Executive Officer
		(Principal Executive Officer)

	By	/s/ Jeffrey S. Points
		Jeffrey S. Points
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

3036


			As of June 30, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	47,361	$	—	$	—	$	47,361
U.S. government securities	20,229		1		—		20,230
Corporate debt	57,134		12		(12)		57,134
Asset backed securities	10,922		10		(1)		10,931
Total available-for-sale debt securities	$	135,646	$	23	$	(13)	$	135,656